US20120004128A1

US20120004128A1 - Fast results hybrid capture assay and associated strategically truncated probes

Info

Publication number: US20120004128A1
Application number: US13/114,344
Authority: US
Inventors: Richard Mallonee; Peter Qiu
Original assignee: Qiagen Gaithersburg LLC
Current assignee: Qiagen Gaithersburg LLC
Priority date: 2010-05-25
Filing date: 2011-05-24
Publication date: 2012-01-05
Also published as: WO2011149897A1; EP2576840A1; EP2576840B1; JP6153866B2; CA2799205A1; AU2011258501B2; AU2011258501A1; JP2013534810A; US9376727B2

Abstract

Strategically truncated probes specific for high-risk HPV nucleic acids, and methods for making and using the same, are disclosed herein. The disclosed probes, and methods of use thereof, permit fast and reliable detection of human papillomavirus in clinical samples without significant cross-reaction.

Description

REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent Application No. 61/347,941, filed on May 25, 2010, the entire contents of which are hereby incorporated by reference.

BACKGROUND OF THE INVENTION

1. Field of the Invention
The present invention relates to methods, reagents, high throughput systems, and kits for determining the presence of a nucleic acid in a sample.
2. Background of the Invention
The detection and characterization of specific nucleic acid sequences and sequence changes have been utilized to detect the presence of viral or bacterial nucleic acid sequences indicative of an infection, the presence of variants or alleles of mammalian genes associated with disease and cancers, and the identification of the source of nucleic acids found in forensic samples, as well as in paternity determinations.
For example, the RNA or DNA for many microorganisms and viruses have been isolated and sequenced. Nucleic acid probes have been examined for a large number of infections. Detectable nucleic acid sequences that hybridize to complementary RNA or DNA sequences in a test sample have been previously utilized. Detection of the probe indicates the presence of a particular nucleic acid sequence in the test sample for which the probe is specific. In addition to aiding scientific research, DNA or RNA probes can be used to detect the presence of viruses and microorganisms such as bacteria, yeast and protozoa as well as genetic mutations linked to specific disorders in patient samples.
Nucleic acid hybridization probes have the advantages of high sensitivity and specificity over other detection methods and do not require a viable organism. Hybridization probes can be labeled, for example with a radioactive substance that can be easily detected, or with biochemical markers such as, for example, biotin, that allows for their capture and detection. Highly sensitive strategically-truncated probes may also be constructed by eliminating sequence regions exhibiting cross-reactive with undesirable or unwanted regions. Nucleic acid molecules may also by captured by a first antibody that is specific to DNA hybrids, wherein the hybrids may comprise DNA-RNA hybrids, DNA-DNA hybrids or RNA-RNA hybrids. The hybrids may subsequently be detected by a second, labeled, antibody that may be, for example, labeled with a biochemical marker such as alkaline phosphatase or any other marker capable of detection.
As nucleic acid sequence data for genes from humans and pathogenic organisms accumulates, the demand for fast, cost-effective, and easy-to-use tests increases. There is a need to provide novel and effective methods, compositions, and kits for determining a target nucleic acid in a sample faster and more. The methods and assays of the present invention meet these needs and may be used in high throughput automated systems. In another aspect, the methods and assays may be implemented in partially automated systems.

BRIEF SUMMARY OF THE INVENTION

In one aspect, the present disclosure relates to polynucleotide probes at least 1 kilobase in length wherein the polynucleotide probe is capable of hybridizing to a high risk HPV nucleic acid, but does not cross-react with a low risk HPV nucleic acid. In one aspect, the polynucleotide probe comprises at least one sequence having from 70% to 100% complementarity to at least 100 contiguous bases of each of L1, L2, E1, E2, E4, E6, and E7 of a high risk HPV nucleic acid, wherein said polynucleotide probe. In a further aspect, the polynucleotide probe does not contain any sequences of at least 100 contiguous bases which have about 70% to 100% complementarity to at least 100 contiguous bases of a low risk HPV nucleic acid. In another aspect, the polynucleotide probe does not comprise any sequences having about 70% to 100% identity to SEQ ID NO: 44 to SEQ ID NO: 57, SEQ ID NO: 111 to SEQ ID NO: 115, or a complement thereof. In yet a further aspect, the polynucleotide probe is specific for a high risk HPV nucleic acid selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 17 and SEQ ID NO: 104 to SEQ ID NO: 110, SEQ ID NO: 116, or a complement thereof. In another aspect, the polynucleotide probe comprises a sequence having about 70% to 100% identity to a sequence selected from the group consisting of SEQ ID NO: 97 to SEQ ID NO: 103 or a complement thereof. In yet another aspect, the polynucleotide probe consists essentially of or consists of a sequence selected from the group consisting of SEQ ID NO: 97 to SEQ ID NO: 103 or a complement thereof.
In an aspect, the present disclosure provides for a nucleic acid comprising a sequence at least 1 kilobase in length sharing 70% or more; 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 116, SEQ ID NO: 117 or a complement thereof, with the proviso that said nucleic acid does not comprise any sequences sharing 70% or more; 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identity with SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, or a complement thereof.
The present disclosure also provides for a probe set of one or more probes comprising, consisting essentially of, or consisting of a nucleic acid sharing 70% or more; 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 116; SEQ ID NO: 117, or a complement thereof, with the proviso that said nucleic acid does not comprise any sequences sharing 70% or more; 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identity with SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, or a complement thereof.
In an aspect, the disclosure provides for a method for determining the presence of a target nucleic acid molecule in a sample including:
a) suspending the sample in a collection medium;
b) releasing target nucleic acid molecules from the sample into the collection medium;
c) converting double-stranded target nucleic acid molecules to single-stranded target nucleic acid molecules;
d) contacting one or more polynucleotide probes with the single-stranded target nucleic acid molecules under conditions that allow the polynucleotide probes and target single-stranded target nucleic acid molecules to hybridize forming double-stranded nucleic acid hybrids;
e) capturing the double-stranded nucleic acid hybrids;
f) separating the double-stranded nucleic acid hybrids from un-bound single-stranded target nucleic acid molecules; and
g) detecting the double-stranded nucleic acid hybrids, thereby indicating the presence of the target nucleic acid.
In an aspect, the polynucleotide probe is a strategically-truncated probe specific for a high risk HPV nucleic acid, wherein the deleted portion shares high sequence identity or cross reactivity to a HPV low risk type. In an aspect, the HPV high risk strategically-truncated probe is specific for or capable of hybridizing to one or more HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 82 and the deleted portion exhibits cross reactivity or specificity with one or more of low risk HPV types 1, 2, 3, 4, 5, 6, 8, 11, 13, 30, 34, 40, 42, 43, 44, 53, 61, 67, 69, 70, 71, 72, 74, 81, 83, 84, and 89. In another aspect, the deleted portion of the probe comprises a sequence sharing 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identity to SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57. In another aspect, the polynucleotide probes are nucleic acid sequences sharing 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identity to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, OR SEQ ID NO: 117, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, or a complement thereof.
Another aspect relates to the rapid detection of target nucleic acid molecules in a sample using the probes disclosed herein. The detection method may be automated, either fully automated, or partially automated—in other words requiring some human input.
Another aspect relates to the detection of target nucleic acid molecules in multiple samples at the same time or within a very short period of time, for example in a machine or a series of machines, using the probes disclosed herein.
Another aspect relates to a kit for the detection of a target nucleic acid molecule in a sample comprising the probes disclosed herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 exhibits the sequence for an exemplary template which can be used to generate strategically-truncated probes specific for HPV33. Underlined text indicates binding sites for the deletion primers. Hatched underlining indicates overlapping sites for the deletion primers. Lower-case text indicates sequences selected for truncation. Template sequences can be found at SEQ ID NO: 5 (including vector sequences) and SEQ ID NO: 104 (HPV sequences only).

FIG. 2 exhibits the sequence for an exemplary template which can be used to generate strategically-truncated probes specific for HPV39. Underlined text indicates binding sites for the deletion primers. Hatched underlining indicates overlapping sites for the deletion primers. Lower-case text indicates sequences selected for truncation. Template sequences can be found at SEQ ID NO: 7 (including vector sequences) and SEQ ID NO: 105 (HPV sequences only).

FIG. 3 exhibits the sequence for an exemplary template which can be used to generate strategically-truncated probes specific for HPV52. Underlined text indicates binding sites for the deletion primers. Hatched underlining indicates overlapping sites for the deletion primers. Lower-case text indicates sequences selected for truncation. Template sequences can be found at SEQ ID NO: 10 (including vector sequences) and SEQ ID NO: 106 (HPV sequences only).

FIG. 4 exhibits the sequence for an exemplary template which can be used to generate strategically-truncated probes specific for HPV56. Underlined text indicates binding sites for the deletion primers. Hatched underlining indicates overlapping sites for the deletion primers. Lower-case text indicates sequences selected for truncation. Template sequences can be found at SEQ ID NO: 11 (including vector sequences) and SEQ ID NO: 107 (HPV sequences only).

FIG. 5 exhibits the sequence for an exemplary template which can be used to generate strategically-truncated probes specific for HPV58. Underlined text indicates binding sites for the deletion primers. Hatched underlining indicates overlapping sites for the deletion primers. Lower-case text indicates sequences selected for truncation. Template sequences can be found at SEQ ID NO: 12 (including vector sequences) and SEQ ID NO: 108 (HPV sequences only).

FIG. 6 exhibits the sequence for an exemplary template which can be used to generate strategically-truncated probes specific for HPV66. Underlined text indicates binding sites for the deletion primers. Hatched underlining indicates overlapping sites for the deletion primers. Lower-case text indicates sequences selected for truncation. Template sequences can be found at SEQ ID NO: 14 (including vector sequences) and SEQ ID NO: 109 (HPV sequences only).

FIG. 7 exhibits the sequence for an exemplary template which can be used to generate strategically-truncated probes specific for HPV68. Underlined text indicates binding sites for the deletion primers. Hatched underlining indicates overlapping sites for the deletion primers. Lower-case text indicates sequences selected for truncation. Template sequences can be found at SEQ ID NO: 15 (including vector sequences) and SEQ ID NO: 110 (HPV sequences only).

FIG. 8 exhibits the sequence for an exemplary template which can be used to generate strategically-truncated probes specific for HPV26 (SEQ ID NO: 116). Underlined text indicates binding sites for the deletion primers. Hatched underlining indicates overlapping sites for the deletion primers. Lower-case text indicates sequences selected for truncation.

FIG. 9 exhibits the sequence for an exemplary template which can be used to generate strategically-truncated probes specific for HPV73. Underlined text indicates binding sites for the deletion primers. Hatched underlining indicates overlapping sites for the deletion primers. Lower-case text indicates sequences selected for truncation.

FIG. 10 exhibits a restriction map of the HPV26XX strategically-truncated probe and its sequence (SEQ ID NO: 117). Deletion primer binding sites are indicated by single underlining, with primer overlap indicated by hatched underlining. The promoter site is indicated by bolded, italicized, and double underlined text. Shaded text indicates probe sequences.

FIG. 11 exhibits a restriction map of the HPV33X strategically-truncated probe and its sequence. Deletion primer binding sites are indicated by single underlining, with primer overlap indicated by hatched underlining. The promoter site is indicated by bolded, italicized, and double underlined text. Shaded text indicates probe sequences.

FIG. 12 exhibits a restriction map of the HPV39XX strategically-truncated probe and its sequence. Deletion primer binding sites are indicated by single underlining, with primer overlap indicated by hatched underlining. The promoter site is indicated by bolded, italicized, and double underlined text. Shaded text indicates probe sequences.

FIG. 13 exhibits a restriction map of the HPV52X strategically-truncated probe and its sequence. Deletion primer binding sites are indicated by single underlining, with primer overlap indicated by hatched underlining. The promoter site is indicated by bolded, italicized, and double underlined text. Shaded text indicates probe sequences.

FIG. 14 exhibits a restriction map of the HPV56XX strategically-truncated probe and its sequence. Deletion primer binding sites are indicated by single underlining, with primer overlap indicated by hatched underlining. The promoter site is indicated by bolded, italicized, and double underlined text. Shaded text indicates probe sequences.

FIG. 15 exhibits a restriction map of the HPV58X strategically-truncated probe and its sequence. Deletion primer binding sites are indicated by single underlining, with primer overlap indicated by hatched underlining. The promoter site is indicated by bolded, italicized, and double underlined text. Shaded text indicates probe sequences.

FIG. 16 exhibits a restriction map of the HPV66XX strategically-truncated probe and its sequence. Deletion primer binding sites are indicated by single underlining, with primer overlap indicated by hatched underlining. Note that “***” indicates the site at which the primers pHPV66XF1 (SEQ ID NO: 76) and pHPV66XR1 (SEQ ID NO: 77) would bind in the template. The promoter site is indicated by bolded, italicized, and double underlined text. Shaded text indicates probe sequences.

FIG. 17 exhibits a restriction map of the HPV68XX strategically-truncated probe and its sequence. Deletion primer binding sites are indicated by single underlining, with primer overlap indicated by hatched underlining. The promoter site is indicated by bolded, italicized, and double underlined text. Shaded text indicates probe sequences.

FIG. 18 exhibits a restriction map of the HPV73XX strategically-truncated probe and its sequence. Deletion primer binding sites are indicated by single underlining, with primer overlap indicated by hatched underlining. The promoter site is indicated by bolded, italicized, and double underlined text. Shaded text indicates probe sequences.

FIG. 19 exhibits a sample schematic for generating truncated HR-HPV probes. As show in FIG. 19, a plasmid comprising the deletion probe is generated according to the following steps: 1. The target HPV template plasmid is methylated. 2. Plasmids are amplified, minus the targeted deletion, using two primers with overlapping tails (deletion primers). 3. The resulting PCR products are linear double stranded DNA minus the segment targeted for deletion. 4. The PCR plasmid mixture is transformed into wild-type E. coli. The host cell circularizes the deleted plasmid and expressed McrBC nuclease digests the original methylated target plasmid. This leaves only the unmethylated truncated plasmid which is replicated. Linear probes may then be generated from the truncated plasmid, such as by the exemplary method at FIG. 31.

FIG. 20 demonstrates a sample schematic for generating the HPV 26XX strategically-truncated probe. 1. A methylated plasmid bearing the HPV26 sequence according to GenBank accession number X74472 was amplified with the primer pair p26F and p26R1 set forth at A to generate single strategically-truncated plasmid HPV26X, which is then cloned. The binding site for each primer is indicated on plasmid HPV 26 v2. 2. After cloning, HPV26X is amplified using the primer pair p26XF3 and p26XR3 to generate HPV26XX. The binding site for each primer is indicated on plasmid HPV 26X.

FIG. 21 exhibits a restriction map and a sample digestion of HPV26XX strategically-truncated plasmid.

FIG. 22 demonstrates a sample schematic for generating the HPV 33X strategically-truncated plasmid.

FIG. 23 demonstrates a sample schematic for generating the HPV 52X strategically-truncated plasmid.

FIG. 24 demonstrates a sample schematic for generating the HPV 58X strategically-truncated plasmid.

FIG. 25 demonstrates a sample schematic for generating the HPV 39XX strategically-truncated plasmid.

FIG. 26 demonstrates a sample schematic for generating the HPV 56XX strategically-truncated plasmid.

FIG. 27 demonstrates a sample schematic for generating the HPV 66XX strategically-truncated plasmid.

FIG. 28 demonstrates a sample schematic for generating the HPV 68XX strategically-truncated plasmid.

FIG. 29 demonstrates a sample schematic for generating the HPV 73XX strategically-truncated plasmid.

FIG. 30 demonstrates the results of a sequence alignment between high risk and low risk HPV-types using Vector NTI 10.3.0 software (Invitrogen Corp., Carlsbad, Calif.). Shaded cells indicate sequences having a high risk of cross-reactivity. Sequences having from about 70% to 100% sequence identity are deemed to have a high risk of cross-reactivity. Sequences having from about 75% to 100% sequence identity are deemed to have a moderately high risk of cross-reactivity. Sequences having from about 80% to 100% sequence identity are deemed to have very high risk of cross-reactivity.

FIG. 31 demonstrates an exemplary scheme for generating linearized probes from truncated plasmids. To introduce uniformity, each template is cloned from L2 to L1 as XhoI/Not I fragments with a promoter sequence (ctcactatagggcgaattgg) (SEQ ID NO: 96). Cloned in this manner, all of the HPV nucleic acids are in the same orientation and can be linearized with one enzyme, XhoI, prior to RNA transcription. The T7 polymerase initiates RNA transcription at the promoter sequence, which terminates at the end of L1 to produce the full length probe without including any of the vector sequence. The sequence of each linearized RNA probe generated in this manner is set forth at SEQ ID NO: 97-105.

DETAILED DESCRIPTION OF THE INVENTION

The present disclosure includes methods, compositions, reagents, systems, and kits for rapidly determining the presence of a nucleic acid molecule in a sample. The methods, compositions, reagents, systems, and kits may be used for clinical diagnostic purposes, including but not limited to the detection and identification of pathogenic organisms and the detection of a genetic predisposition to a particular disease.
In an aspect, nucleic acid probes are disclosed, said probes having the ability to detect a first HPV nucleic acid without substantially cross-reacting with a second HPV nucleic acid.
In one aspect, said nucleic acid probes are generated by a method comprising: a) providing a template nucleic acid comprising a sequence at least 1 kilobase in length sharing from about 70% to 100% identity with the first nucleic acid; b) comparing the sequence of the template nucleic acid with the sequence of the second nucleic acid; and c) truncating any regions of the template nucleic acid that share from about 70% to 100% identity with a region of the second nucleic acid.
In an aspect, the present disclosure provides for a nucleic acid comprising a sequence at least 1 kilobase in length sharing 70% or more; 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 116, or SEQ ID NO: 117, or a complement thereof, with the proviso that said nucleic acid does not comprise any sequences sharing 70% or more; 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identity with SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, or a complement thereof.
The present disclosure also provides for a probe set of one or more probes comprising, consisting essentially of, or consisting of a nucleic acid sharing 70% or more; 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 116, or SEQ ID NO: 117, or a complement thereof, with the proviso that said nucleic acid does not comprise any sequences sharing 70% or more; 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identity with SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, or a complement thereof.
In a further aspect, the probe set comprises at least one nucleic acid probe comprising, consisting essentially of, or consisting of a sequence sharing 70% or more; 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identity with a sequence selected from the group consisting of SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, or SEQ ID NO: 103, OR SEQ ID NO: 117, SEQ ID NO: 117, or a complement thereof.
In an aspect, the present disclosure provides for a nucleic acid comprising, consisting essentially of, or consisting of a sequence sharing 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identity to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, OR SEQ ID NO: 117, SEQ ID NO: 117, or fragments or complements thereof.
In one aspect, the present disclosure provides a method for determining the presence of a target nucleic acid molecule in a sample. The method includes:
a) suspending the sample in a collection medium comprising a detergent;
b) denaturing the target nucleic acid molecule;
c) contacting one or more polynucleotide probes with the target nucleic acid molecule under conditions that allow the probes and the target nucleic acid molecule to hybridize, thereby forming a double-stranded nucleic acid hybrid;
d) capturing the double-stranded nucleic acid hybrid on a solid support coated with a first antibody specific for the double-stranded hybrid nucleic acid hybrid, thereby forming a double-stranded nucleic acid hybrid/solid support complex;
e) separating the double-stranded nucleic acid hybrid/solid support complex from unbound nucleic acid;
f) conjugating the complex with a second antibody that is specific for either the double-stranded nucleic acid hybrid or specific for the first antibody to form a double-stranded nucleic acid hybrid/solid support antibody complex; wherein the second antibody is labeled with a detectable marker;
g) washing the double-stranded nucleic acid hybrid/solid support antibody complex with a wash buffer comprising a detergent; and
h) detecting the label on the second antibody wherein the detecting indicates the presence of the target nucleic acid molecule.
In another aspect, the present disclosure provides a method for determining the presence of a target nucleic acid molecule in a sample including suspending a sample in a collection medium including a detergent; denaturing a target nucleic acid molecule; contacting one or more polynucleotide probes with the target nucleic acid molecule under conditions that allow the probes and the target nucleic acid molecule to hybridize or bind, and capturing the double-stranded nucleic acid hybrid on a solid support coated with a first antibody specific for the double-stranded hybrid nucleic acid hybrid.
In an aspect, the present disclosure provides a method for determining the presence of a target nucleic acid molecule in a sample including suspending a sample in a collection medium including a detergent; denaturing a target nucleic acid molecule; contacting one or more polynucleotide probes with the target nucleic acid molecule under conditions that allow the probes and the target nucleic acid molecule to hybridize or bind, capturing the double-stranded nucleic acid hybrid on a solid support coated with a first antibody specific for the double-stranded hybrid nucleic acid hybrid and separating the double-stranded nucleic acid hybrid/solid support complex from unbound nucleic acid.
In an aspect, the present disclosure provides a method for determining the presence of a target nucleic acid molecule in a sample including suspending a sample in a collection medium including a detergent; denaturing a target nucleic acid molecule; contacting one or more polynucleotide probes with the target nucleic acid molecule under conditions that allow the probes and the target nucleic acid molecule to hybridize or bind, capturing the double-stranded nucleic acid hybrid on a solid support coated with a first antibody specific for the double-stranded hybrid nucleic acid hybrid, thereby forming a double-stranded nucleic acid hybrid/solid support complex; and separating the double-stranded nucleic acid hybrid/solid support complex from unbound nucleic acid; conjugating the complex with a second antibody that is specific for either the double-stranded nucleic acid hybrid or specific for the first antibody to form a double-stranded nucleic acid hybrid/solid support antibody complex.
In another aspect, the present disclosure provides a method for determining the presence of a target nucleic acid molecule in a sample including suspending a sample in a collection medium including a detergent; denaturing a target nucleic acid molecule; contacting one or more polynucleotide probes with the target nucleic acid molecule under conditions that allow the probes and the target nucleic acid molecule to hybridize or bind, capturing the double-stranded nucleic acid hybrid on a solid support coated with a first antibody specific for the double-stranded hybrid nucleic acid hybrid, thereby forming a double-stranded nucleic acid hybrid/solid support complex; and separating the double-stranded nucleic acid hybrid/solid support complex from unbound nucleic acid; conjugating the complex with a second antibody that is specific for either the double-stranded nucleic acid hybrid or specific for the first antibody to form a double-stranded nucleic acid hybrid/solid support antibody complex; wherein the second antibody is labeled with a detectable marker; and washing the double-stranded nucleic acid hybrid/solid support antibody complex with a wash buffer comprising a detergent.
In another aspect, the present disclosure provides a method for determining the presence of a target nucleic acid molecule in a sample, the method comprising:

- a) suspending the sample in a collection medium comprising a detergent;
- b) denaturing the target nucleic acid molecule in the sample;
- c) forming a double-stranded nucleic acid hybrid by contacting at least one polynucleotide probe with the target nucleic acid molecule;
- d) forming a double-stranded nucleic acid hybrid-support complex by capturing the double-stranded nucleic acid hybrid on a support, wherein the support comprises a first antibody;
- e) forming a double-stranded nucleic acid hybrid-support-second antibody complex by contacting the double-stranded nucleic acid hybrid-support complex with a second antibody, wherein the second antibody is labeled with a detectable marker;
- f) washing the double-stranded nucleic acid hybrid-support-second antibody complex with a wash buffer; and
- g) detecting the marker on the second antibody wherein the detecting indicates the presence of the target nucleic acid molecule.

In an aspect, the polynucleotide probes used in the methods described herein are HPV high-risk strategically-truncated probes. In another aspect, the polynucleotide probes are HPV high risk probes and the deleted portion exhibits high sequence identity or cross reactivity to a HPV low risk type. In an aspect, the HPV high risk probe is specific for or capable of hybridizing to one or more of HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 82 and the deleted portion shares cross reactivity or specificity with one or more of low risk HPV types 1, 2, 3, 4, 5, 6, 8, 11, 13, 30, 34, 40, 42, 43, 44, 53, 61, 67, 69, 70, 71, 72, 74, 81, 83, 84, and 89. In another aspect, the polynucleotide probes comprise, consist, or consist essentially of a sequence sharing 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identity to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, or SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, or SEQ ID NO: 103, OR SEQ ID NO: 117, SEQ ID NO: 117, or fragments or complements thereof.
In one aspect, the solid support includes a modified paramagnetic bead that is coated or has attached thereto a first antibody immunospecific for double-stranded hybrid nucleic acids. A magnetic field can be used to separate the double-stranded nucleic acid-magnetic bead-antibody complex from non-bound nucleic acid.
In an aspect, the method does not include a sample pre-treatment step. For example, the detergent-based collection medium allows for reduced sample preparation time which, in turn, can lead to accelerated detection of target nucleic acid molecules. The sample can be analyzed by methods, assays, or the apparatus of the disclosure in a direct-to-assay manner. In an example, purification steps are not performed on the sample prior to evaluation using assays of the disclosure. In an aspect, crude lysate is directly analyzed by the methods, assays, or the apparatus of the disclosure. In another aspect, the sample does not undergo a target amplification step.
One aspect relates to a method of diagnosing cancer by utilizing methods, kits, assays, and the apparatus provided herein. In one aspect, cervical cancer is detected by identifying nucleic acid molecules associated with HPV and HPV variants. In another aspect, cervical intraepithelial neoplasia (CIN) can be screened for using methods, kits, assays, and the apparatus provided herein. The detected cancer can be subsequently treated after being diagnosis by the methods, kits, assays, and the apparatus provided herein. In an aspect, the diagnosed cancer is cervical cancer and variants thereof.
In an aspect, the disclosure provides for a composition comprising
(a) a biological sample suspended in about 0.5% to about 2.0% NP-40, about 0.10% to about 0.40% sodium deoxycholate, about 25 mM to about 75 mM Tris-HCl, about 10 mM to about 50 mM EDTA, about 50 mM to about 200 mM NaCl, and about 0.01% to about 0.10% sodium azide; and
(b) one or more polynucleotide probes.
In an aspect, the disclosure provides for a composition comprising
(a) a biological sample suspended in a collection medium comprising about 0.5% to about 2.0% NP-40, about 0.10% to about 0.40% sodium deoxycholate, about 25 mM to about 75 mM Tris-HCl, about 10 mM to about 50 mM EDTA, about 50 mM to about 200 mM NaCl, and about 0.01% to about 0.10% sodium azide;
(b) one or more polynucleotide probes; and
(c) a first antibody.
In an aspect, the disclosure provides for a composition comprising
(a) a biological sample suspended in a collection medium comprising about 0.5% to about 2.0% NP-40, about 0.10% to about 0.40% sodium deoxycholate, about 25 mM to about 75 mM Tris-HCl, about 10 mM to about 50 mM EDTA, about 50 mM to about 200 mM NaCl, and about 0.01% to about 0.10% sodium azide;
(b) one or more polynucleotide probes;
(c) a first antibody; and
(d) a second antibody.
In an aspect, the disclosure provides for a composition comprising
(a) a biological sample suspended in a collection medium comprising about 0.5% to about 2.0% NP-40, about 0.10% to about 0.40% sodium deoxycholate, about 25 mM to about 75 mM Tris-HCl, about 10 mM to about 50 mM EDTA, about 50 mM to about 200 mM NaCl, and about 0.01% to about 0.10% sodium azide;
(b) one or more polynucleotide probes;
(c) a support coated with a first antibody; and
(d) a second antibody.
In an aspect, the disclosure provides for a composition comprising
(a) a biological sample suspended in a collection medium, wherein the collection medium comprises at least one detergent;
(b) a denaturation reagent;
(c) one or more polynucleotide probes;
(d) a support coated with a first antibody; and
(e) a second antibody labeled with a detectable marker.
In an aspect, the polynucleotide probes used in the compositions described herein are HPV high-risk strategically-truncated probes. In another aspect, the polynucleotide probes are HPV high risk probes and the deleted portion exhibits high sequence identity or cross reactivity to a HPV low risk type. In an aspect, the HPV high risk probe is specific for or capable of hybridizing to one or more of HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 82 and the deleted portion shares cross reactivity or specificity with one or more of low risk HPV types 1, 2, 3, 4, 5, 6, 8, 11, 13, 30, 34, 40, 42, 43, 44, 53, 61, 67, 69, 70, 71, 72, 74, 81, 83, 84, and 89. In another aspect, the polynucleotide probes are nucleic acid sequences sharing 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identity to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, or SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, or SEQ ID NO: 103, OR SEQ ID NO: 117, SEQ ID NO: 117, or fragments or complements thereof.
As used herein, the phrase “high risk HPV” refers to HPV types associated with an elevated risk of developing cancer, which are well known to a person having ordinary skill in the art.
As used herein, the phrase “low risk HPV” refers to HPV types that are not associated with an elevated risk of developing cancer, which are well known to a person having ordinary skill in the art.
In an aspect, any of the above compositions may be used may be used with any of the collection mediums described herein. In an aspect, the biological sample in the above compositions is a cervical cell sample or a human cervical cell sample. In another aspect, the nucleic acid molecules in the biological sample are denatured. The biological sample in the above compositions can exhibit stability when stored in the collection medium for at least 21 days at 33° C. In an aspect, the second antibody is labeled with a detectable marker.

Biological Sample

Methods of the present disclosure may be used to detect the presence of a target nucleic acid molecule from samples, including, without limitation, a specimen or culture (e.g., cellular, microbiological and viral cultures) including biological and environmental samples. Biological samples may be from an animal, including a human, fluid, solid (e.g., stool) or tissue, as well as liquid and solid food and feed products and ingredients such as dairy items, vegetables, meat and meat by-products, and waste. Environmental samples include environmental material such as surface matter, soil, water and industrial samples, as well as samples obtained from food and dairy processing instruments, apparatus, equipment, utensils, disposable and non-disposable items.
The biological samples may include, but are not limited to, cervical epithelial cells (e.g., a sample obtained from a cervical swab), adenoid cells, anal epithelial cells, blood, saliva, cerebral spinal fluid, pleural fluid, milk, lymph, sputum and semen. The sample may comprise a double-stranded nucleic acid molecule or may comprise a single-stranded nucleic acid molecule. If a double-stranded nucleic acid molecule is present, it may be prepared for hybridization analysis by a variety of methods known in the art, e.g., using alkali, using proteinase K/SDS, chaotropic salts. The process of preparing a double-stranded nucleic acid molecule for hybridization analysis generally involves converting it into a single-stranded nucleic acid molecule. This process is generally known as denaturation. However, it is also contemplated that a double-stranded nucleic acid molecule may be detected without denaturation, e.g., through a triple-stranded construct.
The target nucleic acid molecule in a sample can be DNA or RNA or both DNA and RNA. The target nucleic acid molecule can be contained within a larger nucleic acid molecule. Detection of either the target nucleic acid molecule or the larger nucleic acid molecule containing the target nucleic acid molecule is contemplated by this disclosure.
The biological sample may comprise cervical cells, especially human cervical cells. The sample can be collected with any method or device known in the art, including a chemically inert collection device such as a DACRON tipped swab. Other acceptable collection devices may be used including, but not limited to, cotton swab, cervical brush, flocked swab (a swab shaped like a DACRON swab but made with nylon fibers enabling collection of more cells and easier release of cells), cervical broom, mini broom, lavage, or any collection device often used in Pap smear testing.
In an aspect, the methods include collecting a sample from a woman at least 30 years of age. The method can also include collecting a sample from a woman at least 30 years via a Pap smear or comparable test. The sample collected by the Pap smear or comparable test can be a cervical cell sample.
Once the sample is collected, it may be placed in a sample tube. The tube can be sealed to prevent contamination. The collection device (swab, brush, etc.) may further contain a mechanism by which it can be moved once it is inside the sample tube. In one aspect, the collection device contains an insert that can be moved using a magnet. In one aspect, this insert comprises a metal. In another aspect, this insert comprises a magnetic material. Magnetic material includes paramagnetic, ferromagnetic, and diamagnetic materials. One advantage of moving the collection device once it is inside the sample tube is to avoid the collection device from making contact with any sample extraction or sample detection devices. Examples of a sample extraction device include pipettes, automated pipettor, and pipette tips. Examples of sample detection devices include probes and probe tips.

Sample Tube

Any type of sample tube may be used. The sample tube may be closed or sealed to minimize contamination. The closure may be permanent or removable. Examples of removable closures include snap caps, screw caps, rubber septa, foil, and film. The closure may contain one or more openings or perforations, which when pierced may be re-sealable. One advantage of a closure that contains such openings or perforations is that the closure is not rendered ineffective when pierced by, for example, a sample extraction device or sample detection device. Once the sample extraction device or sample detection device is removed, the closure re-seals, thereby minimizing contamination.

Storage of the Biological Sample

Once the sample is in the sample tube, the sample may be stored by drying it with a substrate, or in a preservative medium, or both. Desiccation is accomplished by pressure drying or drying with chemicals. This removes most of the water and is suitable for long-term stability. Alternatively, the sample may be lyophilized (freeze-dried) with a substrate like trehalose to ensure stability of the sample.
Another possibility is that the sample may be stored by suspending in a preservative medium, known and apparent to one of skill in the art. The purpose of the preservative medium is to protect biological components that can degrade. For instance, the sample cells, the probe mixture, the antibody: bead complex used in the capture step, and the secondary antibody used in the detection step are all susceptible to degradation. A preservative medium at the initial step of collection ideally provides sample stability and integrity and can affect downstream steps in the process of nucleic acid capture and detection.

Collection Medium

In an aspect, the sample may be collected and stored in a collection medium. The collection medium has several functions including as a preservative medium to preserve nucleic acids and inhibit nucleases to prevent degradation of nucleic acids prior to analysis. In one aspect, the collection medium contains at least one detergent. In another aspect, the collection medium contains at least two detergents, at least three detergents, or at least four detergents. In an aspect, each of the detergents is different. In another aspect, the detergent-based collection medium comprises two different detergents, one which is able to control background signal and another detergent that improves magnetic bead behavior, for example, migration through a viscous sample, collection, i.e., how well the magnetic beads gather together at the bottom of the sample well, and retention, i.e., how well the magnetic beads stay in place when a supernatant is either removed from a container containing the sample.
In an aspect, heat is employed during the hybridization, capture, and detection steps of the assay. Even with detergent and the application of heat, antibodies used in the assay remain functional.
The detergent-based collection medium may comprise, consist essentially of, or consist of one, two, three, or four or more detergents. Detergents are known in the art and may include, but are not limited to, cationic detergents such as but not limited to cetyl pyridinium bromide, cetyltrimethylammonium bromide (collectively known as cetrimonium compounds) and alkylbenzyldimethylammonium chlorides (collectively known as benzalkonium compounds), and alkyl-trimethyl-ammonium salts; anionic detergents such as, but not limited to, sodium dodecyl sulfate (SDS), and Sarkosyl; and non-denaturing detergents such as NP-40; and other detergents. NP-40 is also known as Tergitol-type NP-40, which is nonyl phenoxylpolyethoxylethanol. NP-40 is not powerful enough to break the nuclear membrane, but can break the plasma membrane. As such, it can be used to obtain the cytoplasmic contents of a cellular culture.
Other detergents and combination of detergents may be used, and their combination provides the ability to control background noise and improve magnetic bead behavior (when the solid support employed comprises magnetic beads). In certain aspects, one detergent is an anionic detergent and the second detergent is a nonanionic detergent. For example, in one aspect, the combination of non-ionic and anionic detergents helps to maintain low-background noise. In an aspect, a detergent-based collection medium comprises an anionic detergent such as sodium deoxycholate, which controls background noise and NP-40, which may improve magnetic bead behavior.
The combination of these two types of detergents provides synergistic benefits beyond a simple combination of adding two detergents together: control of background noise, better bead behavior, and increased assay speed. The presence of these detergents (in the detergent-based collection medium) provides the ability to achieve faster assay results, but does not negatively impact the nucleic acid or capture antibody during downstream analytical steps.
In addition, the detergent-based collection medium improves removal of the specimen from the collection device as the sample is dissolved more easily. In addition, the detergent-based collection medium improves the homogeneity of the sample compared with other collection media such as but not limited to PRESERVCYT (uses a 40% methanol solution), STM (uses a chaotropic agent), and alcohol. The detergent-based collection medium also reduced sample viscosity after mixing (either manual or automated).
The concentration of NP-40 in the collection medium can range from about 0.5% to about 2.0%, from about 0.1% to about 1.0%, as well as any number within the recited ranges. In certain aspects, the NP-40 is present at a concentration from about 0.8% to about 1.5%; from about 0.9% to about 1.2% and in certain aspects is about 1.0%. In another aspect, the NP-40 is present at a concentration from about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1.0%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, or about 2.0%. The concentration of sodium deoxycholate in the collection medium can range from about 0.10% to about 0.40%, from about 0.20% to about 0.30%, as well as any number within the recited ranges. In one aspect, the concentration of sodium deoxycholate is about 0.10%, about 0.15%, about 0.20%, about 0.25%, about 0.30%, about 0.35%, or about 0.40%.
The detergent-based collection medium may comprise, consist essentially of, or consist of a buffer, two detergents, a chelator and a preservative. The buffer may be Tris-HCl in a concentration of from about 25 mM to about 75 mM; from about 30 mM to about 60 mM; from about 40 mM to about 50 mM, and from about 45 mM to about 55 mM as well as any number within the recited ranges. The buffer may also be Tris-HCl in a concentration of about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, or about 75 mM.
Any preservative can be used and the choice can depend on factors such as desired functionality, minimization side-effects, cost, etc. Suitable preservatives include gentomycin, ProClin, dimersol, and sodium azide. The concentration of the preservative in the collection medium depends on factors such as the type of preservative, its efficacy, its side-effects, etc. For example, for sodium azide, the concentration of sodium azide can range from about 0.01% to about 0.1%, from about 0.025% to about 0.075%, and from about 0.04% to about 0.06%, as well as any number within the recited ranges. The preservative, for example, sodium azide, can also be present at about 0.01%, about 0.02%, about 0.03%, about 0.04%, 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, or about 0.10%.
In one aspect the detergent-based collection medium comprises, consists essentially of, or consists of 1.0% NP-40, 0.25% sodium deoxycholate, 50 mM Tris-HCl, 25 mM EDTA, 150 mM NaCl and 0.09% sodium azide. In another aspect the detergent-based collection medium comprises, consists essentially of, or consists of about 0.5% to about 2.0% NP-40, about 0.10% to about 0.40% sodium deoxycholate, about 25 mM to about 75 mM Tris-HCl, about 10 mM to about 50 mM EDTA, about 50 mM to about 200 mM NaCl, and about 0.01% to about 0.10% sodium azide. In other aspects the detergent-based collection medium comprises, consists essentially of, or consists of about 0.8% to about 1.5% NP-40, about 0.20% to about 0.40% sodium deoxycholate, about 30 mM to about 60 mM Tris-HCl, about 20 mM to about 40 mM EDTA, about 100 mM to about 200 mM NaCl, and about 0.025% to about 0.075% sodium azide. In yet another aspect the detergent-based collection medium comprises, consists essentially of, or consists of about 0.9% to about 1.2% NP-40, about 0.20% to about 0.30% sodium deoxycholate, about 30 mM to about 60 mM Tris-HCl, about 20 mM to about 30 mM EDTA, about 100 mM to about 150 mM NaCl, and about 0.04% to about 0.06% sodium azide.
In an aspect, the collection medium comprises, consists essentially of, or consists of NP-40 and EDTA. In another aspect, the collection medium comprises, consists essentially of, or consists of NP-40, EDTA, and sodium azide. In one aspect, the collection medium comprises, consists essentially of, or consists of sodium deoxycholate, EDTA, and sodium azide. In an aspect, the collection medium comprises, consists essentially of, or consists of about NP-40, sodium deoxycholate, EDTA, and sodium azide. In an aspect, the collection medium comprises, consists essentially of, or consists of NP-40, sodium deoxycholate, Tris-HCl, EDTA, and sodium azide.
In another aspect, the collection medium comprises, consists essentially of, or consists of 0.5% to about 2.0% NP-40 and 10 mM to about 50 mM EDTA. In another aspect, the collection medium comprises, consists essentially of, or consists of 0.5% to about 2.0% NP-40, 10 mM to about 50 mM EDTA, and about 0.01% to about 0.10% sodium azide. In one aspect, the collection medium comprises, consists essentially of, or consists of about 0.10% to about 0.40% sodium deoxycholate, 10 mM to about 50 mM EDTA, and about 0.01% to about 0.10% sodium azide. In an aspect, the collection medium comprises, consists essentially of, or consists of about 0.5% to about 2.0% NP-40, about 0.10% to about 0.40% sodium deoxycholate, 10 mM to about 50 mM EDTA, and about 0.01% to about 0.10% sodium azide. In an aspect, the collection medium comprises, consists essentially of, or consists of about 0.5% to about 2.0% NP-40, about 0.10% to about 0.40% sodium deoxycholate, about 25 mM to about 75 mM Tris-HCl, about 10 mM to about 50 mM EDTA, and about 0.01% to about 0.10% sodium azide.
In an aspect, the collection medium is a non-chaotropic medium. That is, for example, the collection medium does not include a chaotropic medium or chaotropic salts. Without being limited, in an aspect, the collection medium does not include guanidine hydrochloride or urea. A potential advantage of using a non-chaoptropic collection medium is better resuspension of a sample, more reproducible testing, and more uniform testing aliquots relative to a medium which includes a chaotropic medium or chaotropic salts.
An advantage of using a detergent-based collection medium is that it preserves the stability of the sample. A sample stored in a detergent-based collection medium as disclosed is stable for at least 31 days, and, when held at temperatures from 15° C. to 33° C. is stable for at least 21 days. In an aspect, a sample is stable when frozen in a detergent-based collection medium at −20° C. for at least six months. In another aspect, a cervical cell sample is stable for at least 31 days, for at least 21 days when held at temperatures from 15° C. to 33° C., and for at least 6 months in a detergent-based collection medium at −20° C.
A detergent-based collection medium also leads to improved assay performance under rigorous hybridization and capture conditions (for example, at temperatures between 65°-75°) relative to collection medium containing a denaturant.
The presence of one, two, three, four or more detergents can reduce sample viscosity, which aids in the removal of the liquid phase from the magnetic beads, as well as aids in the mixing of samples.
In one aspect, a sample such as blood or an exfoliated cervical cell specimen can be collected and suspended in a detergent-based collection medium. The sample can be is collected with a chemically inert collection device such as a DACRON tipped swab. Any other suitable swab may be used such as nylon fiber swabs. The sample may be stored in a detergent-based collection medium, to prevent degradation of nucleic acids prior to analysis and to maintain stability of the sample.
Samples may be collected in other known collection mediums and then can be used in the methods described herein. Examples of other collection media include PRESERVCYT, SUREPATH, DIGENE Collection Medium (“DCM”), and STM (Sample/Specimen Transport Medium). Certain collection media are nucleic acid specific. For example DCM is not used when the target nucleic acid is RNA. Samples collected in some of these media may require processing before the nucleic acids in the samples can be detected and analyzed. Various methods of processing samples (also known as preparing the samples) are known in the art. For example, cervical cell samples collected for cytological analysis in medium such as PRESERVCYT may be combined with a detergent-based lysis buffer followed by the addition of magnetic beads comprising nucleic acid binding surfaces. In addition, other cell samples collected in other known commonly available collection mediums may be combined with a detergent-based lysis buffer followed by the addition of magnetic beads comprising nucleic acid binding surfaces.
In another aspect, the lysis buffer includes 150 mM Tris-HCl (pH 8.0), 0.09% (w/v) Sodium Azide, 6% (v/v) Triton x-100, 300 mM Diethanolamine (w/v), with a final pH of between 9.3 and about 9.5. In another yet another aspect, the lysis buffer includes between about 100 mM to about 200 mM Tris-HCl at between about pH 7.5 and about 8.5, between about 0.05% and about 0.10% (w/v) sodium azide, between about 2.5% to about 7.5% (v/v) Triton x-100, and between about 200 mM to about 400 mM Diethanolamine (w/v), with a final pH of between 9.0 and about 10.0.

Pre-Treatment

In an aspect, the assay does not include a sample pre-treatment preparation step. In another aspect, the assay does not include sample pre-treatment preparation when a detergent-based collection medium is used. For example, a sample pre-treatment preparation is not required when the detergent-based collection medium comprises, consists essentially of, or consists of about 0.5% to about 2.0% NP-40, about 0.10% to about 0.40% sodium deoxycholate, about 25 mM to about 75 mM Tris-HCl, about 10 mM to about 50 mM EDTA, about 50 mM to about 200 mM NaCl, and about 0.01% to about 0.10% sodium azide. Any combination of the components is also contemplated.
In another aspect, the assay can include a pre-sample treatment preparation step when either PRESERVCYT or SUREPATH are used as the collection medium. The pre-treating may be done manually or may be automated.
One example of an automated pre-treatment machine is a Pre-Analytic System (PAS) instrument that is adapted to process biological samples, including liquid based cytology (LBC) samples into standard 96-well plates containing the extracted sample nucleic acid. In the PAS, samples are processed in a strip of eight test tubes, called the extraction tube unit (ETU). Each ETU corresponds to a row of a 96-well plate. In an aspect, the throughput of the system is about 35 minutes to the completion of the first ETU with subsequent ETUs completed at about 2 minute intervals.
In order to meet the throughput requirements, the instrument can process ETUs in a parallel manner. Each ETU passes through 10 steps before the processing is complete. These steps are grouped with similar steps to create six processing modules, identified by the station letters. The ETUs are moved between the six stations by a six-axis robot at about two minute intervals. Because of incubation times, some steps require the ETU to remain at the station for more than about two minutes. In this case, additional locations are supplied in the station to accommodate a first-in-first-out process.
The PAS can include several components, such as: 1) an ETU transport mechanism; 2) an ETU and ETU gripper; 3) a magnet station for attracting paramagnetic beads; and 4) a pipettor station that transfers concentrated nucleic acid from ETU to plate. The PAS can produce up to ten 96-well plates of extracted DNA from liquid based cytology samples in less than 5 hours for subsequent analysis in an instrument designed to run the method for determining of the presence of the target nucleic acid molecules. The PAS is designed to address some of the current challenges of extracting DNA from liquid based cytology testing including volume of sample required (4 mL), limited automation and the low throughput of manual sample conversion protocol.

Target Nucleic Acid Molecules

The target nucleic acid molecules include, without limitation, nucleic acid molecules found in specimens or cultures (e.g., cellular, microbiological and viral cultures) including biological and environmental samples. The target nucleic acid molecules may be found in biological samples from an animal, including a human, fluid, solid (e.g., stool) or tissue, as well as liquid and solid food and feed products and ingredients such as dairy items, vegetables, meat and meat by-products, and waste. Target nucleic acid molecules may be found in environmental samples and include environmental material such as surface matter, soil, water and industrial samples, as well as samples obtained from food and dairy processing instruments, apparatus, equipment, utensils, disposable and non-disposable items.
The target nucleic acid molecules found in biological samples include, but not limited to cervical samples (e.g., a sample obtained from a cervical swab) or cervical cell samples, adenoid cells, anal epithelial cells, blood, saliva, cerebral spinal fluid, pleural fluid, milk, lymph, sputum, urine and semen. The target nucleic acid molecules may be from other viral, bacteria, mycobacteria or plasmodia, for example cytomegalovirus (CMV), herpes, HIV, H1N1, chlamydia, gonorrhea, Trichomonas vaginalis, Staphylococcus aureus, tuberculosis, SARS-associated coronavirus or influenza. In an aspect the target nucleic acid molecules are 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identical to nucleic acid molecules associated with any one of cervical samples (e.g., a sample obtained from a cervical swab) or cervical cell samples, adenoid cells, anal epithelial cells, blood, saliva, cerebral spinal fluid, pleural fluid, milk, lymph, sputum, urine and semen, other viral, bacteria, mycobacteria or plasmodia, for example cytomegalovirus (CMV), herpes, HIV, H1N1, chlamydia, gonorrhea, Neisseria gonorrhoeae (GC), Chlamydia trachomatis (CT), Trichomonas vaginalis, Staphylococcus aureus, tuberculosis, SARS-associated coronavirus or influenza.
In one aspect, the target nucleic acid molecules are human papillomavirus (HPV) and include genetic variants of HPV. A variant includes polymorphisms, mutants, derivatives, modified, altered, or the like forms of the target nucleic acid. In one aspect, the target nucleic acid is an HPV nucleic acid. In another aspect, the HPV nucleic acid is HPV DNA of a high risk HPV type. In another aspect, the HPV nucleic acid is HPV RNA of a high risk HPV type. In another aspect the target nucleic acids are any one of high risk HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 82 or any one of low risk HPV types 1, 2, 3, 4, 5, 6, 8, 11, 13, 30, 34, 40, 42, 43, 44, 53, 61, 67, 69, 70, 71, 72, 74, 81, 83, 84, and 89.
In another aspect, the target nucleic acid molecule is 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identity to nucleic acid molecules associated with any one of HPV, genetic variants of HPV, HPV DNA of a high risk HPV type, or HPV RNA of a high risk HPV type. In another aspect the target nucleic acids are 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identical to nucleic acid molecules associated with any one of high risk HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 82 or any one of low risk HPV types 1, 2, 3, 4, 5, 6, 8, 11, 13, 30, 34, 40, 42, 43, 44, 53, 61, 67, 69, 70, 71, 72, 74, 81, 83, 84, and 89.
As noted previously, the target nucleic acid molecule may be DNA or RNA. When the target nucleic acid molecule is DNA, the probe is preferably RNA and when the target nucleic acid is RNA, the probe is preferably DNA. However, a DNA probe can be used with DNA target nucleic acid molecule and an RNA probe can be used with RNA target nucleic acid molecule. Also as indicated previously, the target nucleic acid molecule may determine the collection medium used.

Denaturation

After the sample is collected in a detergent-based collection medium as described above, the sample may be treated with a denaturation reagent to render the target nucleic acid molecule accessible to hybridization. In one aspect, the sample is denatured with an alkaline solution. Any alkali that can bring a solution pH to about pH 12, about pH 13, or about pH 14 may be used. Additionally, any alkali that can bring a solution pH to a range of about pH 12 to about pH 13, from about pH 12 to about pH 14, and from about pH 13 to about pH 14 can be used. Suitable concentrations of alkali include from about 1.0 N to about 2.0 N, from about 1.25 N to about 1.75 N, and from about 1.25 N to about 1.5 N, and about 1.5 N as well as any number within the recited ranges. Without being limited, suitable alkali include NaOH and KOH.
In one example, the sample suspended in a detergent-based collection medium can be treated with about one-half volume of 1.75 N NaOH solution. For example, in certain aspects approximately a 50 μl aliquot is removed from a sample suspended in a detergent-based collection medium and approximately 25 μl of 1.75 N NaOH solution is added to the 50 μl aliquot sample. The sample treated with the denaturation reagent can be mixed by hand mixing or mechanical shaking at about 800 rpm, about 900 rpm, about 1000 rpm, between about 600 and about 1000 rpm, or between about 600 and 1200 rpm. In an aspect, the pH of the sample after addition of denaturation reagent can be about 14. In another aspect, the pH can be about pH 12 or pH 13. Such basic pH will both nick and denature a majority of the nucleic acid in the specimen. In addition, alkaline treatment can disrupt interactions between peptides and nucleic acids to improve accessibility of the target nucleic acid and degrade protein.
Alkaline treatment of protein effectively homogenizes the specimen to ensure reproducibility of analysis results for a given sample. It can also reduce the viscosity of the sample to increase kinetics, homogenize the sample, and reduce background by destroying any endogenous single stranded RNA nucleic acids, DNA-RNA hybrids or RNA-RNA hybrids in the sample. It also helps inactivate enzymes such as RNases and DNases that may be present in the sample. One skilled in that art would appreciate that if RNA is the target nucleic acid (as opposed to DNA), different reagents may be preferable including, but not limited to phenol extraction and TCA/acetone precipitation, and guanidinium thiocyanate-phenol-chloroform extraction.
Other methods of denaturation may be employed such as utilizing a heating step, for example, heating the sample to about 95° C. to separate the strands of nucleic acid. Enzymes such as helicase may be used as well. The oil may be silicone oil. In one embodiment, an oil or oil-type substance is added to the sample prior to heating. The oil may have a viscosity of about 0.5 Cst to about 20 Cst, about 1.0 Cst to about 10 Cst, or about 2.0 Cst to about 5 Cst. In an aspect, the volume is about 5 Cst. In an aspect about 10 μl to about 45 μl of the above silicone oil is added to 1 mL or more of collection media and evaluated on an automated platform. One advantage of adding an oil is that the sample is heated more evenly.
In one aspect, 1.5 N to 2.0 N NaOH is added to the sample and heated. In another aspect, 1.75 N NaOH is added to the sample and heated. The sample with denaturation reagent may be heated to about 60° C. to about 80° C. for about 30 minutes, to about 65° C. to about 75° C. for about 30 minutes, to about 67° C. to about 70° C. for about 30 minutes, or to about 70° C. for about 30 minutes, or any number within the recited ranges. In another aspect, the sample with denaturation reagent is heated to about 60° C. to about 80° C. for about 20 to about 40 minutes, or to about 65° C. to about 75° C. for about 20 to about 40 minutes, to about 67° C. to about 70° C. for about 20 to about 40 minutes, or to about 70° C. for about 30 minutes, or any number within the recited ranges. A goal of the described time and temperature conditions is to provide for maximal denaturation of the sample in a minimum amount of time, while leaving the target nucleic acid in a suitable condition for carrying out the remaining steps of hybridization, capture, washing, and detection. Therefore, the sample may be heated in denaturation reagent for about 5 to about 120 minutes, about 10 to about 60 minutes, about 20 minutes to about 40 minutes, about 30 minutes, or any number within the recited ranges. It will be readily understood by one of ordinary skill in the art that longer periods of incubation at lower temperatures, or shorter periods of incubation at higher temperatures, may be balanced to provide a similar effect to the conditions described herein.

Hybridization and Binding of Probes

After the sample containing the nucleic acid is denatured, it is contacted with one or more polynucleotide probes under a condition sufficient for the one or more polynucleotide probes to hybridize to the target nucleic acid in the sample to form a double-stranded nucleic acid hybrid. The probe can be full length, truncated, or synthetic DNA or full length, truncated, or synthetic RNA. If the target nucleic acid is DNA, then the probe may be RNA and if the target nucleic acid is RNA, then the probe may be DNA. Preferably, the one or more polynucleotide probes are diluted in a probe diluent that also can act as a neutralizing hybridization buffer (to neutralize the basic denaturation reagent).
The probe diluent used for DNA or RNA probes will differ due to the different requirements necessary for DNA versus RNA stability. For example, if the probes are RNA, it is preferable to neutralize the sample first and than add the probe or alternatively, add the RNA probe and neutralizing agent (probe diluent) to the sample at the same time as NaOH can destroy RNA. The probe diluent can be used to dissolve and dilute the probe and also help restore the sample to about a neutral pH, e.g., about pH 6 to about pH 9, to provide a more favorable environment for hybridization. Sufficient volume of probe diluent, preferably one-half volume of the sample, may be used to neutralize the base-treated sample.
In an aspect, the probe diluent comprises a buffer, polyacrylic acid, NaOH and sodium azide. The probe diluent may comprise acetic acid. In one aspect, the probe diluent comprises 2.2 M BES (N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid), 2.6% polyacrylic acid (PAA), 0.7 N NaOH and 0.09% sodium azide. The probe diluent may contain from about 1.2 M to about 2.6 M BES, from about 1.5 M to about 2.5 M BES; from about 1.75 M to about 2.25 M BES; from about 2 M to 2.4 M BES, or about 2.2 M BES, as well as any number within the recited ranges. In one aspect the probe diluent may contain from about 2% to about 3.0% PAA or, as well as any number within the recited ranges. In another aspect, the PAA concentration is from about 2.2% to about 2.7%. In yet another aspect, the PAA concentration is about 2.6%. In a further aspect the probe diluent may contain from about 0.6 N to about 0.8 N NaOH, for example, about 0.7 N NaOH. The concentration of NaOH generally increases as the amount of BES increases.
The probe diluent has a viscosity that permits accurate dispensing by automatic pipetting techniques. In other words, the viscosity of the probe diluent is adjusted so that the desired volume can be accurately and automatically pipetted. If the viscosity is too low, the probe diluent cannot form a stable drop. On the other hand, if the viscosity is too high, the probe diluent drop will be too large. When such a drop enters the sample tube, it may cause significant disturbance of the contents already in the sample tube (e.g., by splashing against the walls of the sample tube).
For full length probes, a heated alkaline solution may be added to the sample, then probe diluent may be added to the sample at room temperature, and then the sample may be reheated. Such a process can inhibit secondary structure from forming. Antibodies tend to irreversibly bind to structures with secondary structure. When using non-full length probes such as truncated or synthetic probes, heating the solutions or sample may not be necessary because secondary structures issues are not present. In an aspect, the sample is not heated when used with truncated or synthetic probes.
After treatment with the denaturation reagent, an aliquot of neutralization buffer, in an aspect the probe diluent described, in which the one or more probes are dissolved, can be added to the sample under appropriate conditions to allow hybridization or binding of the probe and the target nucleic acid to occur. The neutralization buffer may contain a single buffering salt. In an aspect, the neutralization buffer does not contain more than a single buffering salt. The hybridization condition is sufficient to allow the one or more polynucleotide probes to anneal to a corresponding complementary nucleic acid sequence, if present, in the sample to form a double-stranded nucleic acid hybrid.
Hybridization conditions suitable for the particular probes and diluents described herein are employed. For example, the probes and sample nucleic acids can be incubated for a hybridization time, preferably at least about 5 to about 30 minutes, about 5 to about 20 minutes, or from about 7 to about 15 minutes, or about 10 minutes, as well as any number within the recited ranges sufficient to allow the one or more polynucleotide probes to anneal to a corresponding complementary nucleic acid sequence. The hybridization condition can include a hybridization temperature of at least about 65° C., about 68.5° C., and about 67° C. to about 70° C., as well as any number within the recited ranges. For a given target nucleic acid and a given probe, one of ordinary skill in the art can readily determine desired hybridization conditions by routine experimentation. One of ordinary skill in the art will further appreciate that the time and temperature of hybridization must be optimized, one with respect to the other. Thus, higher hybridization temperatures may be carried out for shorter periods of time and vice versa. Without being limited, stringent hybridization conditions may be controlled by increasing the temperature, increasing the ionic conditions to above 0.5M (for example, NaCl), or reducing the concentration of PAA. As a non-limiting example, stringent hybridization conditions may include performing a hybridization reaction at elevated temperatures, such as of at least about 65° C., at least about 68.5° C., between about 67° C. to about 70° C., and between about 69° C. to about 70° C. Stringent hybridization conditions may also include elevated temperatures, such as of at least about 65° C., at least about 68.5° C., and between about 67° C. to about 70° C.
In a non-limiting aspect, the probe is capable of hybridizing or binding to nucleic acid molecules 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identical to nucleic acid molecules associated with HPV, genetic variants of HPV, HPV DNA of a high risk HPV type, or HPV RNA of a high risk HPV type, or any one of high risk HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 82 or any one of low risk HPV types 1, 2, 3, 4, 5, 6, 8, 11, 13, 30, 34, 40, 42, 43, 44, 53, 61, 67, 69, 70, 71, 72, 74, 81, 83, 84, and 89. In another aspect, the probe is complementary to HPV, genetic variants of HPV, HPV DNA of a high risk HPV type, HPV RNA of a high risk HPV type, or any one of high risk HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 82 or any one of low risk HPV types 1, 2, 3, 4, 5, 6, 8, 11, 13, 30, 34, 40, 42, 43, 44, 53, 61, 67, 69, 70, 71, 72, 74, 81, 83, 84, and 89. In another aspect, the probe is a strategically-truncated probe 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identical to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, or SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, or SEQ ID NO: 103, OR SEQ ID NO: 117, or complements thereof.
In one aspect, the sample is suspended in detergent-based collection medium, the target nucleic acid is denatured with a denaturation reagent, and hybridized to nucleic acid probes suspended in a neutralizing buffer. In another aspect the neutralizing buffer is the probe diluent of the present invention. The probe diluent can comprises 2.2 M BES (N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid), 2.6% polyacrylic acid, 0.7 N NaOH and 0.09% sodium azide.

Capture

After the probes are allowed to hybridize to the target nucleic acid molecule and to form a double-stranded nucleic acid hybrid, the hybrid is captured by a molecule that is specific for the double-stranded nucleic acid hybrid. Molecules specific for the double stranded nucleic acid hybrids include, but are not limited to, monoclonal antibodies, polyclonal antibodies, proteins such as but not limited to RNAse H, nucleic acids including but not limited to aptamers, or sequence specific nucleic acids. Aptamers are short stretches of random sequences that are successively selected from a library of sequences by hybridizing to a target, amplifying the hybridized aptamers, and repeating the selection process. In one aspect the molecule specific for the double stranded nucleic acid hybrid is captured by an antibody, known as an anti-hybrid antibody.
In one aspect, a first anti-hybrid antibody is immobilized onto a support using techniques that are standard in the art. Examples of suitable supports include covalent linkages or adsorption, for example, protein-protein interactions, protein-G beads, biotin-streptavidin interaction, EDAC to link to a carboxyl or tosyl group, etc., or hybridization directly onto the solid support using, for example, sequence specific nucleic acids in an affinity column.
Supports include but are not limited to beads, magnetic beads, which as indicated previously include paramagnetic, diamagnetic, ferromagnetic, ferromagnetic, and diamagnetic beads, columns, plates, filter paper, polydimethylsiloxane (PDMS), and dipsticks. Any support can be used as long as it allows extraction of the liquid phase and provides the ability to separate out bound and unbound antibodies. Magnetic beads are particularly useful in that they can be left in the solution and the liquid phase can be extracted or decanted, if a magnetic field is applied to immobilize the beads. Beads that are small and have a high surface area are preferable, such as beads about 1 μm in diameter. Other beads that employ charge switching or silica capture (as opposed to magnetic fields) may be used as well.
The hybrids are incubated with the anti-hybrid antibody attached to the support for a sufficient amount of time to allow capture of the double-stranded nucleic acid hybrids by the immobilized anti-hybrid antibodies. In an aspect, the support is a bead.
The anti-hybrid antibody may be monoclonal or polyclonal. In one aspect the antibody is monoclonal. In one aspect, the antibody is coupled to support by an 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDAC) linker. In one aspect, the support is a polystyrene bead. In an aspect, the support or bead coupled to the antibody is diluted in a bead dilution buffer. The bead dilution buffer is helpful in minimizing protein denaturation on the bead. One example of a bead dilution buffer comprises 6% casein, 100 mM Tris-HCl, 300 mM NaCl, and 0.05% sodium azide.
In an aspect, the beads coated with the anti-hybrid antibody are incubated with the sample at about 67° C. to about 70° C. for about 30 minutes. In another aspect, the beads and sample are incubated at about 68° C. to about 69° C. for about 30 minutes. In yet another aspect, the beads and sample are incubated at about 68.5° C. for 30 minutes. The incubation time can range from about 5 minutes to about 60 minutes, from about 15 minutes to about 45 minutes, from about 20 minutes to about 40 minutes, or any number within the recited ranges, and is generally inversely proportional to the temperature. It will be understood by those skilled in the art that the incubation time, temperature and/or shaking conditions can be varied to achieve alternative capture kinetics as desired.
Following capture of the target nucleic acid/probe hybrid as described above, the captured hybrid may be separated from the rest of the sample by washing away of non-captured nucleic acids.

Conjugation

Another step in the method can involve providing a second antibody that is also specific for double stranded nucleic acids hybrids or alternatively is specific for the first antibody. The second antibody may be detectably labeled, either directly or indirectly, and may be a monoclonal or polyclonal antibody. In an aspect, the second antibody is monoclonal. In another aspect, the second antibody is directly labeled with a detectable marker and is monoclonal. The second antibody is used to detect the presence of double-stranded nucleic acid hybrids. In one aspect, the second antibody has a label that must react with a substrate to provide a signal that can be detected. The second antibody may be dissolved in a suitable buffer. In one aspect the buffer comprises 100 mM TrisHCl, pH 7.4, 0.5 M NaCl, 0.1 mM ZnCl₂, 1.0 mM MgCl₂, 0.25% Tween 20, 0.2 mg/ml RNase A, 4% hydroxypropyl-b-cyclodextrin (cyclodextrin), 30% bead dilution buffer as discussed previously, 0.05% goat IgG, 0.09% sodium azide. In an aspect, the conjugation reaction takes place at room temperature. In another aspect the conjugation reaction takes place at about 37° C., about 45° C., or about 50° C. In an aspect the conjugation reaction takes place at about 37° C., about 45° C., or about 50° C., between 35° C. and about 40° C., between 40° C. and about 50° C. for between about 20 minutes and 40 minutes. In an aspect the conjugation reaction takes place at about 37° C., about 45° C., or about 50° C. for between about 20 minutes and 40 minutes. In another aspect the conjugation reaction takes place at about 45° C. for about 30 minutes.
It will be understood by those skilled in the art that any detectable label such as, but not limited to, an enzyme, radioactive molecule, fluorescent molecule, or metal particle such as gold particle can be used. In certain aspects, the detectable label is alkaline phosphatase. Methods of conjugating a label to an antibody are known. For example, an antibody can be reduced with dithiothreitol (DTT) to yield monovalent antibody fragments. The reduced antibody can then be directly conjugated to maleinated alkaline phosphatase by the methods of Ishikawa et al., J. Immunoassay 4:209-237 (1983) and Means et al., Chem. 1: 2-12 (1990), the contents of each of which are incorporated herein by reference in its entirety, and the resulting conjugate can be purified by HPLC. The conjugate may also be purified using any type of size-exclusion chromatography. One benefit of purification is that the conjugates of one protein to one antibody can be separated from those conjugates with other ratios of protein to antibody.
In another aspect, the double-stranded nucleic acid hybrids can be detected with a second anti-hybrid antibody that is not directly labeled. For example, the second antibody can be a mouse immunoglobulin that is detected by a labeled goat anti-mouse antibody.

Wash

Following conjugation with the second antibody, the sample is washed with a based wash buffer. The wash buffer may contain one or more detergents or may be free of a detergent. If the wash buffer contains a detergent, the detergent may be an ionic or a non-ionic detergent. One example of a non-ionic detergent is Triton-X. The detergent may be present in the wash buffer at a concentration of about 0.05% to about 1.5%, or from about 0.075% to about 1.0%, or from about 0.1% to about 0.75%, or about 0.5% or any number within the recited ranges. One example of a suitable wash buffer comprises 40 mM Tris, pH 8.2, 100 mM NaCl, 0.5% Triton-X 100 and 0.05% sodium azide.
In an aspect, the wash buffer contains 0.5 mM to about 2.0 mM Tris and 0.02-0.10% sodium azide at a pH between about 7.5 to about 8.5. In another aspect, the wash buffer comprises, consists essentially of, or consists of about 0.5 mM to about 2.0 mM Tris and 0.02-0.10% sodium azide at a pH between about 7.5 to about 8.5. In yet another aspect, the wash buffer comprises, consists essentially of, or consists of about 1.0 mM Tris and about 0.09% sodium azide. In an aspect, the wash buffer has a pH of between about 7.6 to about 8.4.
The sample may be washed with the wash buffer from one to ten times, or from three to seven times, or from four to six times, four times, or five times, or any number within the recited ranges. In an aspect, the sample is washed at least four times with two different wash buffers. In another aspect, the sample is washed at least four times with three washes taking place with one buffer and another wash step taking place with a different buffer. The sample may also be washed with a single wash buffer or with multiple wash buffers. Each wash may use the same wash buffer or a different wash buffer. For example, a detergent-containing wash buffer may be used for one wash while a detergent-free wash buffer may be used for another wash. In an aspect, one of the wash buffers does not include Triton.

Detection

The label present on the second, or third, or more, antibody is detected to thus indicate the presence of the target nucleic acid molecule. Methods for detecting various labels are known in the art. For example, colorimetry, radioactive, surface plasmon resonance, or chemiluminescence methods are described by e.g., Coutlee et al., J. Clin. Microbiol. 27:1002-1007 (1989), the contents of which are incorporated herein by reference in its entirety.
For example, a bound alkaline phosphatase conjugate can be detected by chemiluminescence with a reagent such as a LUMI-PHOS 530 reagent (Lumigen, Detroit, Mich.) or DR2 (Applied Biosystems, Foster City, Calif.) using a detector such as an E/LUMINA luminometer (Source Scientific Systems, Inc., Garden Grove, Calif.), an OPTOCOMP I Luminometer (MGM Instruments, Hamden, Conn.), or the like, such as a Veritas Microplate Luminometer by Turner Biosystems. In an aspect, a fluorometer may be used to detect the conjugate. Multiple detection techniques can also be used in sequence or in parallel. For example, the conjugate may be detected by chemiluminescence and fluorescence. In another aspect, the conjugate can be detected by chemiluminescence.
Detectors using different detection techniques for the conjugate may be reversible or irreversibly attached, for example in a modular fashion, to a machine that is capable of performing the method for determining the presence of a target nucleic acid molecule in a sample.
As described herein, detection of the label on the second antibody is indicative of the presence of one or more of the target nucleic acid molecules in the sample that are complementary to the one or more probes. Following washing, the sample is suspended in a detection buffer that for example, contains the substrate for the label on the second antibody.
In one aspect, the sample is comprised of cervical cells. The method for determining the presence of a target nucleic acid molecule in a sample of cervical cells comprises suspending the sample in a detergent-based collection medium and mixing by hand mixing. In another aspect the mixing is mechanical. An approximately 50 μl aliquot of the sample is removed and mixed with about 25 μl of a denaturation reagent. The sample is mixed by hand mixing or mechanical shaking at between about 600 to about 1200 rpm for about 30 to about 60 seconds and heated at about 70° C. for about 30 minutes. High risk HPV RNA probes are prepared in a diluent and diluted to about 375 ng/ml. About 40 μl of diluted probe is added to the sample on a 70° C. heating block. The samples are further incubated at approximately 68.5° C. with shaking at about 1150 rpm for about 30 minutes. The supernatant can be removed by a dropper bottle or other low tech device. About 35 μl of the detection reagent is added to the sample. The detection reagent contains a second antibody that is labeled. The second antibody is specific for double-stranded nucleic acid hybrids. The sample containing the detection reagent is incubated at about 45° C. for about 30 minutes, placed on a magnetic rack for about 30 seconds to 3 minutes and the supernatant is decanted. In another aspect the sample containing the detection reagent is incubated at room temperature. The sample is then washed with wash buffer about four or five times.

Anti-Hybrid Antibodies

The double-stranded nucleic acid hybrids formed in accordance with the present invention can be captured and detected using antibodies that are specific to double-stranded nucleic acid hybrids. The antibody is specific to double-stranded hybrids, such as but not limited to RNA-DNA; DNA-DNA; RNA-RNA; and mimics thereof, where mimics refer to molecules that behave similarly to RNA-DNA, DNA-DNA, or RNA-RNA hybrids. The anti-double-stranded nucleic acid hybrid antibody, i.e., the anti-hybrid antibody that is utilized will depend on the type of double-stranded nucleic acid hybrid formed. In one aspect, the anti-hybrid antibody is immunospecific to RNA-DNA hybrids.
It will be understood by those skilled in the art that either polyclonal or monoclonal anti-hybrid antibodies can be used and/or coupled to beads and/or immobilized on a support in the present assay as described below. Monoclonal antibody prepared using standard techniques can be used in place of the polyclonal antibodies. Monoclonal antibodies may be produced by methods that are standard in the art. In an aspect, the antibodies used for capture and detection of the target nucleic acid are monoclonal antibodies. In an aspect, monoclonal antibodies support high stringency incubation temperatures during the capture step. Without being limited, the high stringency incubation temperatures during the capture step may be between about 65° to about 75° C. or between about 68° to about 75° C. The first and second antibodies may be the same for capture and detection (i.e., produced by the same hybrid myeloma cell line) or may be different and produced by different hybrid myeloma cell lines. In one aspect, the first and second monoclonal antibodies used for capture and/or detection are the same and are specific for RNA-DNA hybrids. Also included are immunofragments or derivatives of antibodies specific for double-stranded hybrids, where such fragments or derivatives contain binding regions of the antibody.
For example, a monoclonal anti-RNA-DNA hybrid antibody derived from myeloma cells fused to spleen cells that are immunized with an RNA-DNA hybrid can be used. The hybrid-specific antibody can be purified by affinity purification against RNA-DNA hybrids immobilized on a solid support, for example as described in Kitawaga et al., Mol. Immunology, 19:413 (1982); and U.S. Pat. No. 4,732, 847, the contents of each of which are incorporated herein by reference in their entirety.
Other suitable methods of producing or isolating antibodies, including human or artificial antibodies, can be used, including, for example, methods that select recombinant antibody (e.g., single chain F_vor F_ab, or other fragments thereof) from a library, or which rely upon immunization of transgenic animals (e.g., mice) capable of producing a repertoire of human antibodies (see, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551 (1993); Jakobovits et al., Nature, 362: 255 (1993); and U.S. Pat. No. 5,545,806 and U.S. Pat. No. 5,545,807, the contents of each of which are incorporated herein by reference in their entirety).
In one aspect, the target nucleic acid to be detected is DNA (e.g., HPV genomic DNA or cDNA) or RNA (e.g., mRNA, ribosomal RNA, nuclear RNA, transfer RNA, viral RNA, heterogeneous nuclear RNA), wherein the one or more polynucleotide probes are polyribonucleotides or polydeoxyribonucleotides, respectively. In a preferred aspect, the double-stranded nucleic acid hybrids are DNA-RNA hybrids formed by hybridization of target DNA and probe RNA, and can be detected using an antibody that is immunospecific to RNA-DNA hybrids.
In an aspect of the present invention, a monoclonal anti-RNA-DNA hybrid antibody derived from a hybridoma cell line is used. Such hybridoma cell lines are described in U.S. Pat. No. 4,865,980, U.S. Pat. No. 4,732,847, and U.S. Pat. No. 4,743,535, the contents of each of which are incorporated herein by reference in their entirety. Hybrid-specific monoclonal antibodies may be prepared using techniques that are standard in the art. The hybrid-specific monoclonal antibody may be used for both capturing and detecting the target nucleic acid.
While any vertebrate may be used for the preparation of polyclonal anti-RNA-DNA hybrid antibodies, goats or rabbits are preferred. Preferably, a goat or rabbit is immunized with a synthetic poly(A)-poly(dT) hybrid by injecting the hybrid into the animal in accordance with conventional injection procedures. Polyclonal antibodies may be collected and purified from the blood of the animal with antibodies specific for the species of the immunized animal in accordance with well-known antibody isolation techniques. For the production of monoclonal antibodies, the spleen can be removed from the animal after a sufficient amount of time, and splenocytes can be fused with the appropriate myeloma cells to produce hybridomas. Hybridomas can then be screened for the ability to secrete the anti-hybrid antibody. Selected hybridomas may then be used for injection into the peritoneal cavity of a second animal for production of ascites fluid, which may be extracted and used as an enriched source of the desired monoclonal antibodies incorporated herein by reference.

Polynucleotide Probes

The polynucleotide probes are designed to hybridize or bind with the target nucleic acid molecules. In another aspect, the polynucleotide probes are designed to bind to target nucleic acid molecules. In one aspect, the probes are capable of hybridizing or binding to HPV and HPV high risk variants. In an additional aspect, the polynucleotide probes are specific for HPV and HPV high risk variants. High risk (HR) nucleic acid probes can include probes for HPV high risk types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 82. In another aspect, High Risk nucleic acid probes can include probes for HPV high risk types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 82. In other aspects the RNA or DNA probes are fragments. In an aspect, the probes are about 6 to about 8 kilobases in length, about 7.5 kilobases, and may be produced using a plasmid template using a BLUESCRIPT vector. However, other plasmids, vectors and methods are known in the art and could also be used to produce the RNA probes described herein.
The probes may vary in amount from about 7.5 ng to about 60 ng per HPV type per assay, or from about 20 ng to about 45 ng per HPV type per assay, or about 30 ng of probe for each HPV type per assay is used. Thus, in one aspect the HR probes consist of or consist essentially of one or more probes for HPV high risk types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 82 or low risk HPV types 1, 2, 3, 4, 5, 6, 8, 11, 13, 30, 34, 40, 42, 43, 44, 53, 61, 67, 69, 70, 71, 72, 74, 81, 83, 84, and 89 wherein about 30 ng of each probe is used per assay for detection of the target nucleic acid molecule.
In another aspect, a combination or set of nucleic acid molecules is targeted. For example, a set of target nucleic acid molecules can include high risk HPV types 16, 18, and 45. In an aspect, the set of nucleic acid molecules to be targeted include only high risk HPV types 16, 18, and 45. Further, a set of target nucleic acid molecules can comprise, consist essentially of, or consist of polynucleotide probes hybridize with or are specific for high risk HPV types 16, 18, and 45 and may be used with any of the methods disclosed herein.
The RNA probes may be short synthetic RNA probes that specifically bind only to the target nucleic acid molecule. Examples are described in U.S. patent application Ser. No. 12/426,076, filed on Apr. 17, 2009, the contents of which are incorporated herein by reference in its entirety.
In certain aspects a probe mixture comprising multiple sets of probes is used to simultaneously screen for any one of a mixture of desired target nucleic acids. For example, it may be desirable to screen a biological sample for the presence of any HR HPV type. In such a situation, a probe set 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identical to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, or SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, or SEQ ID NO: 103, OR SEQ ID NO: 117, SEQ ID NO: 117 may be used. For example, a probe mixture can be designed to provide a probe set for every HR HPV so one test can be run to identify whether the sample had any HR HPV target nucleic acid.

Strategically Truncated Probes

In an aspect, the strategically-truncated probes are capable of hybridizing, binding to, or are specific for HPV high-risk types. In another aspect, the strategically-truncated probes are capable of hybridizing, binding to, or are specific for HPV high risk types and the deleted portion exhibits high sequence identity or cross reactivity to a HPV low risk type. In another aspect, the strategically-truncated probes are truncated at both the E1 and E2 positions of the HPV sequence where identity with LR types tends to be highest (See FIGS. 1-9). The strategically-truncated probes may also be truncated at the E1, E2, and L1 positions of the plasmid (See FIGS. 1, 4, 7-8) or truncated at the E1, E2, and L2 positions of the plasmid (See FIG. 9) in areas of the HPV genome showing high sequence identity with the low risk types.
In a further aspect, the total amount of deleted sequence in the one (X) or two (XX) deletions range from approximately 1.4 to 2.4 Kb. In another aspect, the deletion is from about 100 to about 200 base pairs, from about 150 to about 300 base pairs, from about 200 to about 500 base pairs, from about 500 to about 1000 base pairs, from about 1200 to about 1500 base pairs, or from about 1000 to about 2000 base pairs. In another aspect, a first deletion is from about 150 to about 300 base pairs or about 200 to about 500 base pairs and a second deletion is from about from about 1200 to about 1500 base pairs or from about 1000 to about 2000 base pairs. In another aspect, the deleted portion exhibits high sequence identity, cross reactivity, or hybridizes to a HPV low risk type, such as to low risk HPV types 1, 2, 3, 4, 5, 6, 8, 11, 13, 30, 34, 40, 42, 43, 44, 53, 61, 67, 69, 70, 71, 72, 74, 81, 83, 84, and 89.
In another aspect, the polynucleotide probes are strategically-truncated probes about 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identical to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 116, or SEQ ID NO: 117. In one aspect, the strategically-truncated probes are fragments from about 100 to about 200 base pairs, from about 150 to about 300 base pairs, from about 200 to about 500 base pairs, from about 500 to about 1000 base pairs, from about 1200 to about 1500 base pairs, or from about 1000 to about 2000 base pairs contiguous base pairs in length of SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 116, or SEQ ID NO: 117.
In an aspect, the one or more polynucleotide probes include a probe set of one or more probes sharing at least about 75% or more, 80% or more, 85% ore more, 90% or more, 95% or more, 98% or more, or 100% identity to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, or SEQ ID NO: 103, OR SEQ ID NO: 116, or SEQ ID NO: 117. The disclosure also provides for probe sets including one or more, two or more, three or more, four or more, or five or more of the probes described herein.
In an aspect, the strategically-truncated probes are capable of reducing cross reactivity, hybridization, or binding with low risk HPV types. In another aspect, one of more strategically-truncated probes of SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, or SEQ ID NO: 103 are capable of reducing cross reactivity with one or more low risk HPV types 1, 2, 3, 4, 5, 6, 8, 11, 13, 30, 34, 40, 42, 43, 44, 53, 61, 67, 69, 70, 71, 72, 74, 81, 83, 84, and 89.
In one aspect, the present disclosure provides an isolated polynucleotide at least about 50% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identical to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, or SEQ ID NO: 103, OR SEQ ID NO: 117, or fragments or complements thereof.
In one aspect, the disclosure provides for an isolated polynucleotide capable of hybridizing or specifically binding to HPV 26 comprising a sequence 50% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identical to SEQ ID NO: 87 or SEQ ID NO: 97 (26)04 fragments, or complements thereof; an isolated polynucleotide capable of hybridizing or specifically binding to HPV 33 comprising a sequence at least 50% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identical to SEQ ID NO: 88 or SEQ ID NO: 98 (33X), fragments, or complements thereof an isolated polynucleotide capable of hybridizing or specifically binding to HPV 39 comprising a sequence at least 50% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identical to SEQ ID NO: 89 or SEQ ID NO: 99 (39XX) fragments, or complements thereof an isolated polynucleotide capable of hybridizing or specifically binding to HPV 52 comprising a sequence 50% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identical to SEQ ID NO: 90 or SEQ ID NO: 100 (52X), fragments, or complements thereof an isolated polynucleotide capable of hybridizing or specifically binding to HPV 56 comprising a sequence 50% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identical to SEQ ID NO: 91 or SEQ ID NO: 101 (56XX) fragments, or complements thereof an isolated polynucleotide capable of hybridizing or specifically binding to HPV 58 comprising a sequence 50% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identical to SEQ ID NO: 92 or SEQ ID NO: 102 (58X), fragments, or complements thereof an isolated polynucleotide capable of hybridizing or specifically binding to HPV 66 comprising a sequence 50% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identical to SEQ ID NO: 93 or SEQ ID NO: 103 (66XX) fragments, or complements thereof an isolated polynucleotide capable of hybridizing or specifically binding to HPV 68 comprising a sequence 50% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identical to SEQ ID NO: 94 or SEQ ID NO: 104 (68XX), fragments, or complements thereof; and an isolated polynucleotide capable of hybridizing or specifically binding to HPV 73 comprising a sequence 50% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identical to SEQ ID NO: 95 or SEQ ID NO: 105 (73XX), fragments, or complements thereof.
In another aspect, high risk HPV sequences exhibiting cross-reactivity or specificity to low risk HPV sequences are identified for target deletions. Cross-reactivity may be predicted by percent identity from sequence alignments using any known sequence identifying database, such as any of the bioinformatics tools described herein. In an aspect, after the high risk HPV sequences exhibiting cross-reactivity or identity to low risk HPV sequences are identified for target deletions, a portion of the sequence exhibiting cross-reactivity or identity to low risk HPV sequences is removed. A second, third, fourth, fifth or more deletion can be made if significant cross-reactivity is present after the first deletion. In another aspect, deletions are initiated using the Invitrogen GeneTailor™ Site-Directed Mutagenesis System.
Bioinformatics tools can be employed to determine the one or more polynucleotide probes. For example, Oligoarray 2.0, a software program that designs specific oligonucleotides can be utilized. Oligoarray 2.0 is described by Rouillard et al., Nucleic Acids Research, 31: 3057-3062 (2003), which is incorporated herein by reference. Oligoarray 2.0 is a program which combines the functionality of BLAST (Basic Local Alignment Search Tool) and Mfold (Genetics Computer Group, Madison, Wis.). BLAST, which implements the statistical matching theory by Karlin and Altschul (Proc. Natl. Acad. Sci. USA 87:2264 (1990); Proc. Natl. Acad. Sci. USA 90:5873 (1993), is a widely used program for rapidly detecting nucleotide sequences that match a given query sequence One of ordinary skill in the art can provide a database of sequences, which are to be checked against, for example HPV high risk and low risk types 1, 2, 3, 4, 5, 6, 8, 11, 13, 16, 26, 30, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 74, 81, 82, 83, 84, and 89. The target sequence of interest, e.g. HPV 18, can then be BLASTed against that database to search for any regions of identity. Melting temperature (Tm) and % GC can then be computed for one or more polynucleotide probes of a specified length and compared to the parameters, after which secondary structure also can be examined. Once all parameters of interest are satisfied, cross hybridization can be checked with the Mfold package, using the similarity determined by BLAST. The various programs can be adapted to determine the one or more polynucleotide probes meeting the desired specificity requirements. For example, the parameters of the program can be set to prepare polynucleotides of 25nt length, Tm range of 55-95° C., a GC range of 35-65%, and no secondary structure or cross-hybridization at 55° C. or below.

Cross-Reactivity

The present invention also provides for assay compositions, probes, and conditions wherein cross-reactivity between HPV HR probe sets and low risk HPV types is dramatically reduced when compared to the standard FDA approved HPV assay and probe set. In one aspect, the HPV HR probe set is selected from the group consisting of HPV high risk types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 82 or low risk HPV types 1, 2, 3, 4, 5, 6, 8, 11, 13, 30, 34, 40, 42, 43, 44, 53, 61, 67, 69, 70, 71, 72, 74, 81, 83, 84, and 89. Using the present assay with these HR HPV probes, cross-reactivity between low risk HPV types and high risk HPV probes is reduced. See, for example, U.S. patent application Ser. No. 12/426,076.
The present invention also provides a method for determining the presence of a target nucleic acid molecule, such as HPV, in a sample in about 2 hours or less, about 2.5 hours or less, about 3 hours or less, about 3.5 hours or less, about 4 hours or less, about 5 hours or less, about 6 hours or less, about 7 hours or less, about 8 hours or less, about 12 hours or less, about 24 hours or less, in other aspects, less than about 3.5 hours for at least 10 samples using the methods discussed above. One reason why the presence of HPV or other target nucleic acid molecules can be determined in short periods of time is because the method does not amplify the target nucleic acid molecule prior to detection. Instead of target amplification, signal amplification may be used to accurately detect the presence of HPV or other target nucleic acid molecules. In an aspect, the methods of the disclosure may include a signal amplification step. In an aspect, the methods of the disclosure do not include a target amplification step. In another aspect, the methods of the disclosure may include a signal amplification step and no target amplification step.
The present disclosure also provides methods and assays for detecting cancer, for example cervical cancer, by detecting the presence of a target nucleic acid molecule, such as HPV, in a sample in about 2 hours or less, about 2.5 hours or less, about 3 hours or less, about 3.5 hours or less, about 4 hours or less, about 5 hours or less, about 6 hours or less, about 7 hours or less, about 8 hours or less, about 12 hours or less, about 24 hours or less, in other aspects, less than about 3.5 hours for at least 10 samples using the methods and assays as discussed above.
It will be understood to those skilled in the art that the present invention can be carried out on a number of platforms including, but not limited to, tubes, dipsticks, microarrays, microplates, 384 well plates, other microtiter plates and microfluidic systems. It will be understood to those skilled in the art that the present, can be automated.
Another aspect of the present invention provides a collection medium into which samples containing the target nucleic acid are collected. The collection medium provides sample stability for several days, several weeks, or several months. For example, the collection medium may provide sample stability for at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, from about 1 week to about 4 weeks, from about 1 month to about 3 months, from about 3 to about 4 months, or from about 3 month to 6 months. In another aspect, the collection medium provides sample stability for at least 21 days at 33° C. or at least 6 months at 20° C. In an aspect the above sample is a cervical cell sample or a human cervical cell sample. Suitable collection media are described herein. In one aspect, the collection medium comprises, consists of, or consists essentially of NP-40, deoxycholate, Tris-HCl, EDTA, NaCl, and sodium azide. In other aspects, the collection medium comprises, consists of, or consists essentially of 1.0% NP-40, 0.25% sodium deoxycholate, 50 mM Tris-HCl, 25 mM EDTA, 150 mM NaCl, and 0.09% sodium azide.
Another aspect is a detergent-containing wash buffer comprising, consisting of, or consisting essentially of 40 mM Tris pH 8.2, 100 mM NaCl, 0.1% to 0.5% Triton X-100, and 0.09% sodium azide. Yet another aspect is a detergent-free wash buffer comprising, consisting of, or consisting essentially of 40 mM Tris pH 8.2, 100 mM NaCl, and 0.09% sodium azide.

High Throughput Assay

An aspect relates to a high throughput assay and apparatus capable of being practiced with any of the methods or compositions described herein. The high throughput assay is capable of accurately and rapidly processing samples a large number of samples in a short period of time.
In an aspect, the high throughput assay is capable of processing at least 300 samples in less than 3 hours, 900 samples in about 5 hours, at least 1000 samples in about 6 hours, or at least 1500 samples in about 8 hours. In another aspect, the high throughput assay is capable of processing at least 10 microtiter plates (96 well plates, for example) in about 5 hours, at least 15 microtiter plates (96 well plates, for example) in about 7 hours, or at least 20 microtiter plates (96 well plates, for example) in about 8 hours. In an aspect, the processing of samples takes place from the start of the method or assay to the completion.

Kit

Also provided is a kit for the detection of a target nucleic acid molecule in a sample, the kit comprising, consisting of or, or consisting essentially of:
a) a collection medium;
b) a denaturation reagent;
c) a polynucleotide probe;
d) a bead coated with a first anti-hybrid antibody;
e) a detection reagent comprising a second anti-poly hybrid antibody, wherein the second antibody is detectably labeled;
f) a wash buffer; and
g) a second detection reagent comprising a substrate for the label on the second antibody.
The collection medium, denaturation reagent, bead, first and second antibodies, polynucleotide probes, detection reagents, and wash buffers have been previously described.
In an aspect, the kit included one or more HPV high risk probes and the deleted portion shares high sequence identity or cross reactivity to a HPV low risk type. In an aspect, the HPV high risk probe is specific for or capable of hybridizing to one or more of HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 82 and the deleted portion shares cross reactivity or specificity with one or more of low risk HPV types 1, 2, 3, 4, 5, 6, 8, 11, 13, 30, 34, 40, 42, 43, 44, 53, 61, 67, 69, 70, 71, 72, 74, 81, 83, 84, and 89. In another aspect, the polynucleotide probes are nucleic acid sequences sharing 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 100% identity to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, or SEQ ID NO: 117.

Apparatus

An aspect relates to a high throughput apparatus capable of being practiced with any of the methods or compositions described herein. In an aspect, the compositions, methods, assays, and kits described herein are used together with the apparatus described in U.S. patent application Ser. No. 12/508,304, U.S. patent application Ser. No. 12/508,306, U.S. patent application Ser. No. 12/622,131, U.S. patent application Ser. Nos. 12/605,540, and 12/605,605, each of which are incorporated by reference in their entirety. The instruments described in U.S. patent application Ser. No. 12/508,304, U.S. patent application Ser. No. 12/508,306, U.S. patent application Ser. No. 12/622,131, U.S. patent application Ser. Nos. 12/605,540, and 12/605,605 have broad-based applications and are capable of accurately and rapidly processing samples a large number of samples in a short period of time. Without being limited, the systems and instruments described in described in U.S. patent application Ser. No. 12/508,304, U.S. patent application Ser. No. 12/508,306, U.S. patent application Ser. No. 12/622,131, U.S. patent application Ser. Nos. 12/605,540, and 12/605,605, can be used to detect and analyze nucleic acid molecules associated with nucleic acid molecules associated with any one of cervical samples (e.g., a sample obtained from a cervical swab) or cervical cell samples, adenoid cells, anal epithelial cells, blood, saliva, cerebral spinal fluid, pleural fluid, milk, lymph, sputum, urine and semen, other viral, bacteria, mycobacteria or plasmodia, for example cytomegalovirus (CMV), herpes, HIV, H1N1, chlamydia, gonorrhea, Neisseria gonorrhoeae (GC), Chlamydia trachomatis (CT), Trichomonas vaginalis, Staphylococcus aureus, tuberculosis, SARS-associated coronavirus or influenza. Moreover, the systems and instruments described in described in U.S. patent application Ser. No. 12/508,304, U.S. patent application Ser. No. 12/508,306, U.S. patent application Ser. No. 12/622,131, U.S. patent application Ser. Nos. 12/605,540, and 12/605,605 can be used to detect and analyze nucleic acid molecules associated with HPV, genetic variants of HPV, HPV DNA of a high risk HPV type, HPV RNA of a high risk HPV type, or any one of high risk HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 82 or any one of low risk HPV types 1, 2, 3, 4, 5, 6, 8, 11, 13, 30, 34, 40, 42, 43, 44, 53, 61, 67, 69, 70, 71, 72, 74, 81, 83, 84, and 89.

EXAMPLES

Example 1

In order to generate probes specific for HR-HPV having a minimal risk of cross-reacting with LR-HPV, deletion plasmids of each HR-HPV genome were generated. These strategically-truncated plasmids include the full length sequence for each HR-HPV, minus certain regions having a relatively high degree of homology with LR-HPV nucleic acids.

1. Selection of Targets for Deletion

Sequence alignments are performed comparing 15 HR-HPV types ( HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 58, 59, 66, 68, and 82) with 28 LR-HPV types ( HPV 1, 2, 3, 4, 5, 6, 8, 11, 13, 30, 34, 40, 42, 43, 44, 53, 54, 61, 67, 69, 70, 71, 72, 74, 81, 83, 84, and 89) to determine overall sequence similarities. The HR-HPV and LR-HPV sequences used are set forth in Table 1 below:

	TABLE 1

	GenBank Accession	SEQ ID NO

	High Risk HPV
	HPV
16	K02718	1
	HPV 18	AY262282	2
	HPV 26	X74472	3
	HPV 31	JO4353	4
	HPV 33	M12732	5
	HPV 35	M74117	6
	HPV 39	M62849	7
	HPV 45	X74479	8
	HPV 51	M62877	9
	HPV 52	X74481	10
	HPV 56	X74483	11
	HPV 58	D90400	12
	HPV 59	X77858	13
	HPV 66	U31794	14
	HPV 68	DQ080079	15
	HPV 73	X94165	16
	HPV 82	AB027021	17
	Low Risk HPV
	HPV
1	NC_001356	18
	HPV 2	NC_001352	19
	HPV 3	X74462	20
	HPV 4	NC_001457	21
	HPV 5	NC_001531	22
	HPV 6	AF092932	23
	HPV 8	PPH8CG	24
	HPV 11	M14119	25
	HPV 13	X62843	26
	HPV 30	X74474	27
	HPV 34	NC_001587	28
	HPV 40	X74478	29
	HPV 42	M73236	30
	HPV 43	AJ620205	31
	HPV 44	U31788	32
	HPV 53	NC_001593	33
	HPV 54	HPU37488	34
	HPV 55	HPU31791	35
	HPV 61	HPU31793	36
	HPV 62	AY395706	37
	HPV 64	N/A	38
	HPV 67	D21208	39
	HPV 69	AB027020	40
	HPV 70	HPU21941	41
	HPV 71	AB040456	42
	HPV 72	X94164	43

Results of this sequence alignment are shown at FIG. 30. HR sequences showing the highest percentage of identity with LR types are identified for targeted deletions. Based on this, HPV 26, 33, 39, 52, 56, 58, 66, 68, and 73 are selected as candidate plasmids for sequence removal to reduce LR cross-reactivity.

2. Site-Directed Mutagenesis

Based on the HR/LR sequence alignment results, the most homologous region in each HR-HPVs initially are deleted. Bluescript plasmids comprising the full-length HR-HPV sequence of interest are methylated at 37° C. for one hour. The plasmid is then amplified using overlapping amplification primers. One of the amplification primers overlaps with the region of the target selected for deletion, while the other does not. The resulting amplification products thus are unmethylated linear amplicons that correspond to the target sequence, minus the sequence selected for deletion. The target sequence and the amplicons are then transfected into an E. coli strain, which digests the methylated target and circularizes and amplifies the unmethylated linear amplicons. Exemplary workflows for this method are demonstrated at FIGS. 22-29.
The sequence of the sites that have been targeted for deletion are set forth below at Table 2:

TABLE 2

	HPV
SEQ ID	Type
NO	[Length]	Sequence

44	HPV26	CCGTTGTATGCCGGCCTGTAACATAAACTTACGCCCTAGTGGAAATTGA
	[490 bp]	TCCAAATCAATAGAAAATTTTTCTTTTAAATCTACATCCCAAAATTTAAAT
		TTTTGAAAAGGATCTTCCTTTGGCACAGGAGGGGCGTTACGCTGACAGGT
		AGTAGCAGAGTTTTTAATAAACCTATAGGCATCTTCCAAACTAGCAGTGG
		GAGGTAAGGTTAGTCCAAAATTCCAATCCTCCAATATGGAGGCATTCATT
		AAATGTATGTAAGCCATAACATCTGTTGTAAGTGTTATTTTACACAACTGA
		AATATAAATTGTAATTCATATTCTTCGCCATGTCTTATAAATTGTTTATAAT
		CAGATGGTTTAAATGGAGTGGATGCAGATGCTGCAGATAATGTACTAATG
		GTAAGGTTAGTACTGCGGGTGGTATCAACACAGGTAACAAACAATTGATT
		GCCCCAACAGATACCATTATTATGACCCTGTGCACGT

111	HPV26	TTTTGTTTACACACAACAGTAGAGGGCACCACCTGGTGGTTTATACATTGC
	[1514 bp]	ATGTTTCCTTCACGAGCTTTATAAAATATTGCACATTCATATCGTACCAGT
		TTCCAATAATCAATTTGATCAGTTAATTTATTACTGTCCAGTTCATAATAGT
		CTAGTATTTTCTCCTGGCACGCATTTAAACGCTGGCAAAGGTTCTCCATTT
		TCTTTGTCCGCGTCCTCCTCCAAATCTAATCTGGACCAGGTGGTGGAAAAA
		AAGCTTTTCCAATTTACATCAGTCAATGCATATACAGGATTCCCATTGCTG
		TCAAATGGAAATGTATTTGGAAATGGTATCACTGTTACTCTACTATGTAAA
		TACAAAAGTGAGTTATCTTCTTGAGGATTTATATTTGAGGTAATTATTAAT
		GGGGGGCATGTAACTTGCAGTAGGCTTCTATGTTTTCTGTCTATACAACAG
		GGATTTCCATCTAAAAAGTTACGTAAATATTTATCAATATATAACCAGCAG
		CTATATGTAGCATCATCTAATACTGCAACTTTTGCATCTTCTAAAGGCTGC
		AGCCAAAAATGGCTATTTGAATTTACATATGAAATGACTGACCCTTGCATA
		AATTTTATAAAACTCATTGCAAACTGTGACTTACCAGTATTTGGCGGTCCA
		TATATTACTATACAATTGTGCTTTGGGGTACCCTTTAAAAACTGTTTTAAC
		ACTTGTAAAAAATAAATAAAGTTTACATGTTGAAACCTTAAAAATTTGGC
		AATTTCCTTCCACGACCCGCCCTCTTCTATTTTAGAACATCTATATTGTAGC
		CATTGTGACATACACATAGATCGTTTCTGTGCTCTTTTATAATGTCTAGTCA
		TGGTTGCACAGTCTTTTACATATTTTGCCTGACAATTGCTTTTTAAAAAGG
		CAGCTGCATTACTATCTATGTCAGCTAACTGTGCATATTTAAATGCAATTT
		CACTATCATCTGTTATGTCATGATCGAACGCCCATTGCACCATTTTTGATA
		AATCAAATGTAGCATCATCAAAACTATGTTCTAATTGTGTTTGTCGTACTA
		TCCATTCTGGTGTATCTCCATATGTCTCACTTATATTGGACAACCCTGTTTT
		ATAAAAATATAATGCTACTGCTGTACTTCGCAATTTTGGTGGTTCAATTAG
		TAATTGCGTTTCTGGCACATTTAATAACATACATAGGCAGTTTTTAATTGT
		TGTTCTGTTTTTTGCACATGTAAAGCGCACTAGCATTAGTACTATTACTCCC
		CAATTACATGTTAAACATTGTATATGATAATATAAACAATATTGTTGTATT
		AATGATTTAATACTTTCTGCTACAGAGCCTGCCACACCGAATGCTGCACAC
		ACCCAATCTGAACAGCATGTTTTGTCACTTTTAAACACCCGTACTAGTTCT
		GCAAAACTTACACCATATACTGTTTTAAATTTACTTAACAATGCTGCTTTT
		ACATTACTACATTTTAATAATTCACATATTT

45	HPV33	GTCTCTAATGCCATTTGTAGTTCAATTACTTGAAATGCTTTGGTCTTTGA
	[1460 bp]	TGCTAACAAAGAAGGCACCACCTGGTGGCATAAATGTGAAAATCCCATTT
		GTTTGGCTGTATACAATAAAGCACACTCCATGCGTATCAGTTTCCAATGTT
		CAATTTGTGATGGTAAATCAGTTTTATCAGCTTCGTAAAGAGCTAGCATTT
		TCTCCTGCACTGCATTTAAACGTGCTGATATTTCCTCCATGGTTTTCCTTGT
		CCTCTTCCTCTATTAAATCTAATTTGCACCACGTCCTTGAGAAAAAGGATT
		TCCAATTTTCATCATTTATTGCATACACTGGGTTACCATTTTCATCAAATGG
		GAATGGATTTTTAAATTCAAATACTGTTAATCTACTATGTAAATATGGCCA
		TCTAGAGTCTGTGCCTGCATTTGTATTTGAGGTAAGAAGCAGTGGTGGACA
		TTTTAATTGCACTAATGCCCTATGTTTCACATCTATTGAAATTTCATTTCCA
		TCTAACGCATTTCTCATGTAATCATCTATATATGTCCAACTTATTGGCGTTA
		CATCATCTATCATTCCTATTTTTGCATCTGATAATGGCTGCAACCAAAAGT
		GACTTTTAGAATTTACACATGATATAACACACCCTTTTAAAAACTGTATTA
		AACTCATTCCAAAATATGACTTTCCTGTATTTGCTGGTCCACAAATTAGCA
		TACAGCTTTTTTTTGGTATACCTTTTAAAAACTTTTTAAATGCACCTAAAAA
		TGCTGTAAATTCAATGTTTTGATATCTTAACAACTGTACTATTGGTCTCCA
		ATTTCCTCCATCATTTGTTTTTTCACATCTACTTTGTATCCATTGTCCTATTG
		ACATTTTACGTTTTTCTGCTTTTTTATAATGTCTACACATTATTCCACAGTC
		CTTTACTATTTTTGCTTGTGAGTTACTTTTTAAAAATGCAGCAGCATTACTA
		TTTGAATCTGCAAGTTGTGCATAATAATATGCAATGTCACTATCGTCCGTT
		AACTCGTTATCATATGCCCACTGTACCATTTCACTTAAATCAAATATATTA
		TCATTAAAGCTATGTTGTAAAACAGTTAGTCTATCTATCCATTCAGGTGTT
		GTACCTTGTACATCACTAATGTTTGACATTGCTGTTCTAAACCAATACAAT
		GCACATGTTTGGCTCCGTAATTTTGGTGGCTCTATAACCATACATGTTTCA
		GGTATTGATAATAAATTACTCATTAGTTTTGCTACTGTTAACCTGTTTTTGC
		TACACCTAAATCTAATTAACAATAATATTATTATTCCTCTATCGCAAGTTA
		AACATTGTAAATGAGTATACAAACTATGCTGTTTAATTAATACTTTTAAAC
		TTTCTGCTACTGATGGACTAATTCCATATCCTGTTATACACCAATCTGTAC
		AGCTTGTTTTATCACTTTTAAATG

46	HPV33	GTCTCTAATGCCATTTGTAGTTCAATTACTTGAAATGCTTTGGTCTTTGA
	[1459 bp]	TGCTAACAAAGAAGGCACCACCTGGTGGCATAAATGTGAAAATCCCATTT
		GTTTGGCTGTATAAAATATTTCCCTCCATAATGGATCCGTTTCCAATGTTC
		AATTTGTGATGGTAAATCAGTTTTATCAGCTTCGTAAAGATCTAGTATTTT
		CTCCTGCACTGCATTTAAACGTGCTGATATTTCCTCCATCGTTTTCCTTGTC
		CTCTTCCTCTATTAAATCTAATTTGCACCACGTCCTTGAGAAAAAGGATTT
		CCAATTTTCATCATTTATTGCATACACTGGGTTACCATTTTCATCAAATGG
		GAATGGATTTTTAAATTCAAATACTGTTAATCTACTATGTAAATATGGCCA
		TCTAGGGTCTGTGCCTGCATTTGTATTTGAGGTAAGAAGCAGTGGTGGACA
		TTTTAATTGCACTAATGCCCTATGTTTCACATCTATTGAAATTTCATTTCCA
		TCTAACGCATTTCTCATGTAATCATCTATATATGTCCAACTTATTGGCGTTA
		CATCATCTATCATTCCTATTTTTGCATCTGATAATGGCTGCAACCAAAAGT
		GACTTTTCGAATTTACACATGATATAACACACCCTTTTAAAAACTGTATTA
		AACTCATTCCAAAATATGACTTTCCTGTATTTGCTGGTCCACAAATTAGCA
		TACAGCTTTTTTTTGGTATACCTTTTAAAAACTTTTTAAATGCACCTAAAAA
		TGCTGTAAATTCAATGTTTTGATATCTTAACAACTGTACTATTGGTCTCCA
		ATTTCCTCCATCATTTGTTTTTTCACATCTACTTTGTATCCATTGTCCTATTG
		ACATTTTACGTTTTTCTGCTTTTTTATAATGTCTACACATTATTCCACAGTC
		CTTTACTATTTTTGCTTGTGAGTTACTTTTTAAAAATGCAGCAGCATTACTA
		TTTGAATCTGCAAGTTGTGCATAATAATATGCAATGTCACTGTCGTCCGTT
		AACTCGTTATCGTATGCCCACTGTACCATTTCACTTAAATCAAATATATTA
		TCATTAAAGCTATGTTGTAAAACAGTTAGTCTATCTATCCATTCAGGTGTT
		GTACCTTGTACATCACTAATGTTTGACATTGCTGTTCTAAACCAATACAAT
		GCACATGTTTGGCTCCGTAACTTTGGTGGCTCTATAACCATACATGTTTCA
		GGTATTGATAATAAATTACTCATTAGTTTTGCTACTGTTAACCTGTTTTTGC
		TACACCTAAATCTAATTAACAATAATATTATTATTCCTCTATCGCAAGTTA
		AACATTGTAAATGAGTATACAAACTATGCTGTTTAATTAATACTTTTAAAC
		TTTCTGCTACTGATGGACTAATTCCATATCCTGTTATACACCAATCTGTAC
		AGCTTGTTTTATCACTTTTAAATG

112	HPV33	ACAGTTATGTATATAATACATACCTATATAATCTACTTTCCCTGTAACCAT
	[1460 bp]	AGTACATGTATCTTCCTCTATAATATATATTTCACCCCAGTTTGTATAATCC
		ATTGTATTTTTTTTGTCATTGTCATATTGCACAGTTACTGTTTCTCCTTGTTT
		TTTAAAACATTTTGGTGGTTCACAAAGCCACACCTCTAAGCTTGTTTGTTG
		CAATGTCCATTGGCTTGTACTATACTGTGATTTACTTAATGTCTCTAATGCC
		ATTTGTAGTTCAATTACTTGAAATGCTTTGGTCTTTGATGCTAACAAAGAA
		GGCACCACCTGGTGGCATAAATGTGAAAATCCCATTTGTTTGGCTGTATAC
		AATAAAGCACACTCCATGCGTATCAGTTTCCAATGTTCAATTTGTGATGGT
		AAATCAGTTTTATCAGCTTCGTAAAGAGCTAGCATTTTCTCCTGCACTGCA
		TTTAAACGTGCTGATATTTCCTCCATGGTTTTCCTTGTCCTCTTCCTCTATT
		AAATCTAATTTGCACCACGTCCTTGAGAAAAAGGATTTCCAATTTTCATCA
		TTTATTGCATACACTGGGTTACCATTTTCATCAAATGGGAATGGATTTTTA
		AATTCAAATACTGTTAATCTACTATGTAAATATGGCCATCTAGAGTCTGTG
		CCTGCATTTGTATTTGAGGTAAGAAGCAGTGGTGGACATTTTAATTGCACT
		AATGCCCTATGTTTCACATCTATTGAAATTTCATTTCCATCTAACGCATTTC
		TCATGTAATCATCTATATATGTCCAACTTATTGGCGTTACATCATCTATCAT
		TCCTATTTTTGCATCTGATAATGGCTGCAACCAAAAGTGACTTTTAGAATT
		TACACATGATATAACACACCCTTTTAAAAACTGTATTAAACTCATTCCAAA
		ATATGACTTTCCTGTATTTGCTGGTCCACAAATTAGCATACAGCTTTTTTTT
		GGTATACCTTTTAAAAACTTTTTAAATGCACCTAAAAATGCTGTAAATTCA
		ATGTTTTGATATCTTAACAACTGTACTATTGGTCTCCAATTTCCTCCATCAT
		TTGTTTTTTCACATCTACTTTGTATCCATTGTCCTATTGACATTTTACGTTTT
		TCTGCTTTTTTATAATGTCTACACATTATTCCACAGTCCTTTACTATTTTTG
		CTTGTGAGTTACTTTTTAAAAATGCAGCAGCATTACTATTTGAATCTGCAA
		GTTGTGCATAATAATATGCAATGTCACTATCGTCCGTTAACTCGTTATCAT
		ATGCCCACTGTACCATTTCACTTAAATCAAATATATTATCATTAAAGCTAT
		GTTGTAAAACAGTTAGTCTATCTATCCATTCAGGTGTTGTACCTTGTACAT
		CACTAATGTTTGACATTGCTGTTCTAAACCAATACAATGCACATGTTTGGC
		TCCGTAATTTTGGTGGCTCT

47	HPV39	CAGTAGTGGGTACCGATCCGTCACTGGTACTGCACATAGAGTCAGGAC
	[1692 bp]	AATGAATTATGTTGCCATTATAATGCACTTCCCATTTGCCACTAGTCCCAT
		ACCTTTCCGCATCTTGAATAAACACTTCATAGTATACTTTTAGGTGCTCGTT
		CATATAATATATACCCCAATAGTCCACACACCCTTCTGTTTTACACCATAT
		GTCTATATTATTTTTATAATATATAGCACCCCATAATACATAGTTCATAGC
		ATTACATTTGTCCCCATCATACCACACCTCCACTGTAGTTCCTTGTTTTTTA
		AAACATTGTTTTGGCTGTGTATGCCACAGTTCATTACTAGTGTCTTTTAATG
		TCCACTCCTCTGTATTGTATTCAGTTTGTGCAACACTTTCTAGTGCCATCTG
		CAGTTCAATAGCTTGATATGCTTTACATTTTGAAATGTTTATGGTTGGCAC
		CACCTGGTGGTCAATAGTATGCATGCCACGTTCTCGTGCTGCATAAAATAT
		TGCATTTTCCATTCGCACACATTTCCAATAATTAATTTGATCATATATTGAT
		TTACTGTCTTGTTCATAGTATTCTAGTATTTTGTCCTGTAACACATTTAAAC
		GTTGTGAAAGTGTTTTCATCATTGTCTCCTTCATCCTCGTCCTGCTGCAAGT
		CTAATCTGCACCAAGTCTTTTCAAAAAAACATTTCCAGTTTTTATCATTGA
		TTGTGTACACTGGATTCCTGTTTTGGTCAAATGGAAATGCATTAGGAAATT
		TAAACACTGTTAGCCTACTACGTAAATATGGCCACCTATCGTCTTCCACAG
		GATTGGTATTGGAGGTTATTAATAATGGTGGACATTTCATTTGTAGTAAAC
		TTTTATATTTCCTATCTAAACTTATTGCATACCCATCTAATGCATTTCTCAT
		ATAATTATCGAAATATGACCAGCAGGTACCGGTTGCATCATCTAACATTGC
		TAGTTTTGCATCTGCAAGTGGTTCTAGCCAAAAGTGGCTGGTGGAGTTTAC
		ATATGAAATAACTGTGCCCTGTAAAAAATGCATAAGGCTCATACAAAAAT
		GTGACTTTCCTGTATTCGCAGGTCCATATATAACTATACAGTTTTTTTTGGG
		AGTACCCTTTAAAAATTCCTTTAATGCACATAAAAAGGATATAAATTCTAT
		TCCTTGATATCTTAAGAATTGTACTATGGGTCTCCAGTCCCCGCCTTCATC
		ACATTTACTACACCTAAATTTTATCCATTGAGACATGGACATTTGCCTTTTT
		TGTGCTCGCTTGTAATGTTTACACATTGTTGCACAATCTTTTACATATTTTG
		CCTGGCAGTTACTTTTTAAAAAGGCTGCAGCATTACTGTTACAATCTGCTA
		ACATTGCATAATTAAATGCTATGTCACTTTCATCAGTATATTCATTGTCAA
		ATGCCCATTGTACCATGTCCGATAGGTCAAATACACTATCATCTATTCCAT
		GTTGTATAACAGTTAATCGTTGTATCCATTCTGGCGTATCCCCTGTTACCA
		CACTAATATTGGATATACCTGTGCGATACCAATATAGTGCTGCTACAGGGC
		TGCGCAGTTTAGGAGGCTCCAGAAGCATACAACTTTCTGGAACATGTAAC
		AATGTACTTAATCCCTTTCCTACAGTAACCCTATTTTTTCCACATGTATATC
		TT

48	HPV 39	ATACCACCACGATTCCAAAAATGTCTTGCAAACAGTTGTTCCCTACGTA
	[190 bp]	AACAGAAGAACATACTGTCCCCATACACATCTGCAGACATTTGCAAATAA
		TCAGGATATTTACAAATGGATTGACAAATATCTAAAGGCACCTCACTTTTG
		GTTTCCTGCAATGCACCAAAGTCCATAGCTCCATAGCCAG

49	HPV52	TAATAGAACCACCAAAATTACGAAGTGCTACCTGTGCATTATATTGGTA
	[1376 bp]	TAGAACAGGTTTGTCTAATATTAGTGAGGTATATGGTACCACCCCAGAAT
		GGATAGAACAACAAACAGTATTACAGCATAGCTTTGACAATAGCATATTC
		GATTTTGGAGAAATGGTGCAATGGGCATATGATCATGATATAACAGATGA
		TAGTGACATAGCATATAAATATGCACAGTTAGCAGATGTAAATAGCAATG
		CTGCAGCATTCCTAAAAAGCAATTCGCAAGCAAAAATAGTAAAGGACTGT
		GCAACCATGTGTAGACATTATAAACGGGCAGAAAGAAAACATATGAATAT
		TGGACAATGGATACAGTATAGATGTGATAGAATAGATGATGGTGGAGATT
		GGAGGCCTATAGTAAGATTTTTAAGATATCAAGACATAGAATTTACAGCC
		TTTTTAGACGCATTTAAAAAATTTTTAAAAGGTATACCTAAAAAAAATTGT
		TTAGTATTATATGGACCTGCAAACACAGGAAAATCATATTTTGGAATGAG
		TTTAATTAGGTTCTTAAGTGGATGTGTAATATCCTATGTAAACTCAAAAAG
		CCATTTTTGGCTACAACCATTAACAGATGCAAAAGTGGGTATGATAGATG
		ATGTAACACCTATATGTTGGACATATATAGATGATTATATGAGAAATGCA
		CTGGATGGAAATGATATATCAGTAGATGTAAAGCATAGAGCCTTAGTACA
		AATAAAATGCCCACCATTAATTTTAACAACAAATACAAATGCAGGAACAG
		ATCCTAGGTGGCCATATTTACATAGTAGATTGGTTGTGTTTCATTTCAAAA
		ACCCATTTCCATTTGATGAAAATGGCAATCCTATATATGAAATTAACAACG
		AAAATTGGAAATCCTTTTTCTCAAGGACGTGGTGCAAATTAGATTTAATAC
		AGGAAGAGGACAAGGAAAACGATGGAGTCGATACCGGCACGTTTAAATG
		CAGTGCAGGAAAAAATACTAGATCTATACGAAGCTGATAGTAATGACCTA
		AACGCACAAATTGAACATTGGAAATTGACTCGAATGGAATGTGTTTTGTTT
		TACAAAGCAAAGGAACTGGGAATAACTCATATAGGCCACCAGGTGGTGCC
		ACCAATGGCAGTGTCTAAGGCAAAGGCCTGCCAAGCTATTGAACTACAAT
		TGGCATTGGAGGCATTAAACAAAACACAATATAGCACAGATGGATGGACA
		TTACAACAAACAAGTCTAGAAATGTGGCGTGCAGAACCACAAAAATACTT
		TAAAAAACATGGGTATACAATAACAGTGCAATACGATAATGATAAAACAA
		TACTATGGATTATACAAACTGG

50	HPV56	ACGTGGAGGTGGTGGTGGTGGTCTTGTGGGTGTTGTATTCGTTAACAGT
	[1961 bp]	TTCAACAGGGGATACGTTGTATCTACAGGTACTAGACACAGAGTCAGGAC
		AATAAATACTCTCATTTTCCATATGTACTTCCCATATGTTTTTACACCCAAA
		TTTTTTGGCCTCTTGTTCAAAGTCTGTGTAGTATGTTTTGTGGCCATCATGT
		ACATAATATATACCTCTATAGTCTACCCCAGAACACACTTTTTGCCACCCA
		CAATCTCCATTGTAATATATATATTTCCAGGCTACATATTGCATACAATTG
		TTTTTACTACCATCAAACCATACTTCTATATGTTGTCCTTCTTTTTTAAAGC
		ATTTTTTAGGTTCAGTAAGCCATAGTTCCTCGCATGTGTCTCTTAATGTCCA
		CTCTTCATTGTTATATATTGTTGTACTTAATGATTCCAGTGCTATTTGCACT
		TCTATTGCACTACATGCTTTTGCTTTACATACTTGTAAACAAGGCACCATC
		TGGTGGTTTAGTACAGTAATGTCATTTTCTCTTGCTTTATAGTATAGCACAT
		TTTCATGTCGCACAGCTTTCCAATATTCTATATGATCTGCAATACATCTACT
		ATCTTTTTCAAAACAGTCTAGTATTTTGTTCTGGCACGCATTTAAACGTTG
		GGAAAGCGTCTCCATTGTTTTCTTTGTCCTCGTCGTTATCCAAATTTAATCT
		GGACCACGTCCTTGTAAAGAAACATTTCCAGTTTACATTACTTAATTCATA
		TACAGGATTACCATTATTATCTAATGGAAATGGATTTTGAAACTGAAACAC
		TAACATTCTACTGTGTAAATATCGTAATTTAGCATCTAGCATAGGATTTAT
		ATTGGTTGTAATTAGTAATGGTGGACATTTTATTTGTACTAATTGTTTATGT
		TTTCTATCTAAACTTATAGGATTTCCATCTACCAAATTCCTTAAATAATCGT
		CTATATATTTCCAACATATTTCTGTTGCATCATCCAACAACCCAAGTTTAG
		CATTGTCTAATGGCTGCAACCAAAAGTGGCTTTGTGAATTCACAAATGAA
		ATGACAGACCCTTGAAAAAACTTTATAAGACTCATAGCAAAGCATGATTT
		ACCTGTATTTGGCGGTCCACAAAGTACCAAACAGTTATGTTTAGGTGTTCC
		TTGTAGAAATAATTTAAAGTAACTTAGAAATGAAATGAAATCGACCCCTT
		GATATCTTAAAAATTGTACAATGGGTTTCCAATCACCCCCTTCATCTGTTTT
		ACTACATATGTGCTTTATCCACTGGCACATATTCATTTGTTGCTGTTGTGCC
		CTTTTATAATGTCTACACATTATTCCACAATCCTTTACATATTTTGCCTGCA
		TATTGCTTTTTAAAAAGGCTTGTGCATTGCTGTCTACATCTGCTAATTGTGC
		ATATTGAAACGCAATTTGGCTATCATCTGTTACTTCATTATCAAATGCCCA
		CTGCACCATTTTAGATAATTCAAATTGACTATCCTGTAAACTGTGTTGCAA
		TTGTGTTTGTCTTTGTATCCATTCTGGTGTGTCTCCATACACATCACTAATA
		TTTGACATTGCTGTTTTATAAAAATATAAAGCTACAGCAGGACTTCGTATT
		TTTGGTGGTTGAATTAACATTTGCTCCTGTGGTACATTTAATATTGAGCTTA
		ATGCTTTTGCAATTGTTTTTCTGTTTTTGCCACATGTATATCTAATTAGCAT
		CATTACTATAACCCCCCATGTACATGTTAAACATTGCATATGATAATACAT
		ACAGTGTGGTTTTATTATAGTTTTTAGTGCCTCGGCTAATGTTTCATTAACA
		CCAAATATAGCACATATCCAATCATTGCAACATGTACTATCACTTTTAAAC
		GTACGCACCAATTCTGAAAATGGAATACCATACACTTCTTTAAATTTATAA
		TATAATTTACC

113	HPV56	CTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTT
	[1962 bp]	GCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGAT
		AAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGG
		GCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTC
		AGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCA
		CTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAG
		ATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTT
		TTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGA
		GCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTT
		CTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGT
		GGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGG
		CTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTT
		AGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCT
		AATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGG
		GTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAA
		CGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAA
		CTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGG
		GAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAG
		CGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGT
		CGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGG
		GGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCC
		TGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGA
		TTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCG
		CAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAG
		CGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGC
		AGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGC
		AATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTAT
		GCTCCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACAC
		AGGAAACAGCTATGACCATGATTACGCCAAGCGCGCAATTAACCCTCACT
		AAAGGGAACAAAAGCTGGGTACCGGGCCCCCCCTCGAGATGGCGACGTG
		GCGGCCTAGTGAAAATAAGGTGTATCTACCTCCAACACCTGTTTCAAAGG
		TTGTGGCAACGGATTCCTATGTAAAACGCACTAGTATATTTTATCATGCAG
		GCAGTTCACGATTGCTTGCCGTAGGACATCCCTATTACTCTGTGACTAAGG
		ACAATACCAAAACAAACATTCCCAAAGTTAGTGCATATCAATATAGGGTA
		TTTAGGGTACGGTTGCCCGACCCTAATAAGTTTGGGCTTCCAGATACTAAT
		ATTTATAATCCGGACCAGGAACGGTTAGTGTGGGCATGTGTAGGTTTGGA
		GGTAGGCCGCGGACAGCCTTTAGGTGCTGGGCTAAGTGGCCATCCATTGT
		TTAATAGGCTGGATGATACTGAAAGTTCCAATTTAGCAAATAATAATGTTA
		TAGAAGATAGTAGGGACAATATATCAGTTGATGGCAAGCAAACAC
51	HPV56	TTAGCTAATGGGTCCTGTTTTTCTGTTGGTGGCTGTTCCCGTTGACATGT
	[210 bp]	TATAGCTGTGCTTCTAACATATCTATATTTATCTTCTAGGCTGGTGGCCACT
		GGCGGGGATAACCCAATATTCCAGTCCTCCAGTAGGTTAGCATTCATATTA
		TGTAAATATGCCATAACCTCTGCAGACAAAGTAATTTTGCATAATTGAAA
		AACAAAT

52	HPV58	TTGTGATGTTAAATCATTTTTATCAGCTTCGTATATGTCTAGGATTTTGT
	[1300 bp]	CCTGCACTGCACTTAAACGTGCTGATATTTCCTCCATCGTTTTCCTTGTCCT
		CTTCCTCTATTAAGCCTAATTTGCACCACGTCCTTGAGAAAAAGGATTTCC
		AATTTTCATCATTTATTTTATACACTGGATTACCATTTGCATCAAATGGAA
		ATGGATTGTTAAATTCAAATACTGTTAGTCTACTGTGCAAATATGGCCATC
		GTGAATCTTTGCCTGCATTTGTATTTGAGGTAATTATTAATGGTGGACATT
		TTAATTGTACTAATGCCCTATGTTTTACATCTATTGAAATGTCGTTACCATC
		TAATGCATTTCTCATATAATCATCTATATATGTCCAGCTTATGGCTGTTACA
		TCATCTATCATACCTAGTTTAGCATCTGATAATGGCTGCAACCAAAAATGA
		CTTTTGGAATTTACATATGAAATAATGCATCCTTTTAAAAAATGTATTAAA
		CTCATTCCAAAATATGATTTCCCTGTATTTGCTGGGCCACACAGTAACATA
		CAACTTTTTTTTGGTACACCTTGTAAAAACTGTTTAAATGCAACTAAAAAT
		GCTGTAAATTCAATATTTTGATATCTTAAAAATTGTACTATTGGTCTCCAA
		TTACCTCCATCATTTGTTTTTTCACACCTACTTTGTATCCATTGTCCCATTGT
		CATACCACGCTTTTCTGCTCTTTTATAATGTCTGCACATAACGCCACAGTCT
		TTTACTATTTTTGCTTGTGCATTGCTTCTTAAAAATGCTGCTGCATTACTAT
		TAACATCTGCTAACTGTGCATATTTATATGCAATGTCACTATCATCTGTAA
		TGTCATTATCATATGCCCATTGTATCATTTCACTTAAATCAAATATATCATC
		ATTAAAGCTATGCTGTAACACTGTTAATCTATCTATCCATTCTGGTGTTGTC
		CCTTGCACATCACTTATATTTGACATTGCTGTTCTAAACCAATATAAGGCA
		CATGCTTGACTTCGTAATTTTGGTGGCTCGATAATCATACATGTTTCAGGA
		ATTGATAGTAAATTACTCATTAATTTTGCCACAGTTAATCTATTTTTGCTAC
		ATTTAAATCTAATTAACAATAATAATATAATTCCTCTGTCACACGTTAAAC
		ATTGTAGGTGTGTATATATACTGTGCTGTTTAATTAGTACTTTTAAACTTTC
		TGCTACGGAGGGACTTATTCCATACCCTGTTATACACCAATCTGTACAGCT
		TGTTTTATCACTTTT

53	HPV66	TTTTTTAAAACAGTTTTTGGGCTCCGTGCGCCACAGTTCATCACATGTA
	[1655 bp]	TCACGTAATGTCCACTCTTCATTTTTATATATTGTGTTACTTATTGCTTCCA
		GTGCCATTTGTAATTCTATTGCACTACATGCTTTTGCTTTACACACTTGTAA
		AGAGGGCACCATCTGGTGGTTTAGTACATTAATGTCATTTTCTCTTGCTTT
		ATAATATAATACATATTCATGTCGTACAGCTTTCCAATAGTTTATATGATC
		TATAATGCATTTACTATCTTTTTCATAACAGTCTAGTATTTTGTTCTGGCAC
		GCATCTAAACGTTGGGATAGAGTCTCCATTGTTTTCTTTGTCCTCGTCGTTA
		TCCAAATTTAATCTGGACCATGTCCTTTCAAAAAAACATTTCCAATTTACA
		TTACTCAATTCATACACAGGATTACCATTGTTATCTAATGGAAATGGATTT
		TCAAACTTAAACACTGAAATTCTACTGTGTAGATATCCTAATTTTGCATCT
		TGCATAGGATTTACATTAGTTGTAATAATGACTGGAGGACATTTTATTTGT
		ACTAATTGTTTATGTTTCCTATCTAAACTTATGGGATTCCCATCTAATAAAT
		TTCTTAGATAATCATCTATATATCTCCAACACGTATCTGTTGCATCATCCA
		GCAAACCTAATTTGGCATTGTCTAGTGGCTGTAACCAAAAGTGGCTTTGTG
		AATTAACAAATGAAATGACTGACCCTTGGAAAAAATTTATAAGGCTCATA
		GCAAAACATGATTTACCTGTATTTGGTGGTCCACACAGTACCAAACAATTA
		TGTTTAGGCGTGCCTTGTAAAAATAATTTAAAATAACTTAAAAATGAAAT
		GAAGTCGACCCCTTGATATCGTAAAAATTGCACAATGGGTTTCCAATCACC
		AAGCCAAGCTTAATTCGGCTTCCCTTCATCTACTTTACTACATATATGCTTT
		ATCCACTGGCACATATTCATTTGCTGTTGCTGTGCCCTTTTATAATGTCTAC
		ACATTATTCCACAATCCTTTACATATTTTGCTTGCATATTACTTTTTAAAAA
		TGCTTGTGCATTACTATCTATGTCTGCTAGTTGTGCATATAAAAAGGCAAT
		TTGGCTATCATCTGTTACGTCATTATCAAATGCCCACTGTACCATTTTAGA
		CAATTCAAATTGATTGTCTTGTAAACTGTGTTGCAATTGTGTCTGTCTTTGT
		ATCCATTCTGGTGTTTCCCCATACACCTCACTAATATTTGACATTGCTGTTT
		TATAAAAATATAATGCCACAGCAGGACTTCGTAGTTTTGGTGGTTGAATTA
		ACATTTGCTCTTGTGGTACATTTAAAATTGAGCTTAGCGATTTTGTAATTGT
		TTTTCTGTTTTTTCCACATATATATCTAATTAGCATCATTACAATTACCCCC
		CATGAACATGTTAGGCATTGCATATGATAGTACACACATTGTGGTTTTAGT
		ATAGTTTTTAACGCTTCTGCTAATGTTTCATTAACACCAAATATTGCACAT
		ATCCAATCGTTACAACATGTACTATCGCTTTTAAATGTTCGCACCAACTCT
		GTATATGGCACTCCATACACTTCTTTAAATTTAAAATGTAATCTTCCTTGTA
		CGTTACTACTTTTA

114	HPV66	CGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAA
	[1634 bp]	TTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCA
		ACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTA
		TGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCC
		CCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCA
		GAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCAT
		AATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAG
		TACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCT
		TGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAA
		AGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTT
		ACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATC
		TTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAG
		GCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATA
		CTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTC
		TCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGG
		GTTCCGCGCACATTTCCCCGAAAAGTGCCACCTAAATTGTAAGCGTTAATA
		TTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCA
		ATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGA
		TAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAAC
		GTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCC
		ACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAA
		AGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGG
		GAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAG
		CGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACC
		ACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCCCATTCGCCATTC
		AGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATT
		ACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAA
		CGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGC
		GCGTAATACGACTCACTATAGGGCGAATTGGAGCTCCACCGCGGTGGCGG
		CCGCCTGTAAAAAAATAGGGAACACGTTTACGGCGCCTACGTTTAAAAAA
		ATATACAGGCCATAGTGCAAATGTACCTCCCTGTATATATACATCATGTGT
		AACATCATAAGGAGACTGAGGTACAAAGGGCCAAGTACTGGGGCCTGTA
		GGTAAAACTATATCAGGACCA

54	HPV66	GATTACCCCAGCATATGCCATTATTATGGCCCTGTGCACGTTGCAACCA
	[320 bp]	ATAAGGTTTATTAAATAATTGGGCCTCAGAGGTAATCATGGACCCACTAG
		GAGTAGCAACATATACAGAACTGGGAGGAGGGTCCCTGCCATTGCCACCC
		TTCCAATACAAATCTGTAGGAATGGCTTCCCCAACATTACCTGCCCTATTA
		AAGTAATGTTTGGCAAACAATTGTTCCCTGCGTAAGTAAAACCACATAGA
		ATCCCCATAGGCATCTGCAGACATTTTTAGATAATCAGGATATTTACATGT
		AGATTGTACAATGTCCAAT

115	HPV66	GCGTGCCTTGTAAAAATAATTTAAAATAACTTAAAAATGAAATGAAGTCG
	[320 bp]	ACCCCTTGATATCGTAAAAATTGCACAATGGGTTTCCAATCACCAAGCCA
		AGCTTAATTCGGCTTCCCTTCATCTACTTTACTACATATATGCTTTATCCAC
		TGGCACATATTCATTTGCTGTTGCTGTGCCCTTTTATAATGTCTACACATTA
		TTCCACAATCCTTTACATATTTTGCTTGCATATTACTTTTTAAAAATGCTTG
		TGCATTACTATCTATGTCTGCTAGTTGTGCATATAAAAAGGCAATTTGGCT
		ATCATCTGTTACG

55	HPV68	GAGTTTGTTTTTTTGGTGCATGGGGCACCTGCGGTGGTATGGGTCGCGG
	[1930 bp]	TGGTGTTCTGTAGGTCGGCAACAGATTCAGTAGTGGATACTTTTCCGTCAG
		TGGTACTGCACATAGAGTCAGGACAATGGATTATGTTGCCATTATAATGC
		ACGTCCCATTTTCCACTAGTCCCATATAGTTGTGCATCCTGCATAAACCTTT
		CGTAATAGGTTTTTTGTTGTTCATACATATAATATACACCCCAGTAATCCA
		CACGCCCTTGGGTTTTACACCATGTGTCTGTACTGTTTTTAAAGTAAATTGT
		ACCCCACACTACATAATGCATTGAGTTACTCTTGTCCCCATCATACCATAC
		TTCCACTGTAACACCATGTTTTTTAAAACATTGCTTTGGCTTTGTATGCCAT
		AGTTCATTACTTGTGTCCCTTAATGTCCACTCCTCTGCACTATATGCAGTTT
		TAGCAAGGCTCTCTAGTGCCATCTGCAGTTCAATAGCTTGATATGCTTTAG
		TTTTTGAAATGTTTACAGGCGGCACCACCTGGTGGTCAATATTATGCATAC
		CACGTTCTCGTGCTGCATAATATATTGCATTTTCCAGTCGCACACAATTCC
		AATAGTTAATATGGTCCTGTATACATTTACTGTCCTGTTCATAATGTTCTAA
		TATTTTCTCCTGTAACACATTTAAACGTTGGGAAAGTGTTTCCATCATTGTC
		TCCTTCATCCTCGTCCTGCTGCAAGTCTAATCTGCACCAAGTCTTTTCAAA
		AAAACATTTCCAGTTTTTATCATTGATTGTATACACTGGGTTCCTGTTTTGG
		TCAAATGGAAATGCATTAGGAAATTTAAACACGGTTAGTCTACTATGTAA
		ATACGGCCACCTATTGTCTTCTACAGGGTTAGTATTGGATGTTATTAGCAT
		TGGTGGACACTTTATTTGTATTAGGTGTCTGTGTTTTCTATCTAAACTTATT
		GGGTTACCATCTAATGCATTTCTCATGTAATTATCAAAATATGACCAGCAT
		GTACCTGTTGCGTCATCTAGCATGGCTATTTTTGCATCTGCAAGTGGCTCT
		AACCAAAAGTGACTTGCTGAATTTACATATGAAATTATTGTGCCTTGTAAA
		AAATGTATAAGGCTCATGCAAAAATATGACTTGCCTGTATTTGGCGGCCC
		ATGTATAACTATACAATTTCGTTTTGGCGTGCCTTTTAAAAAATCTTTTAAT
		GCACATAAAAATGTTATAAATTCCAGTCCTTGATATCTTAAAAATTGTACA
		ATTGGGCGCCAATCACCGCCTTCGTCACATTTACTGCATCTAAATTTAATC
		CATTGTGGCATTGTCATTTGTCGTTTTTGCGCCCGTTTGTAATGTCTACACA
		TTGTTGCACAATCTTTTACATATTTTGCTTGACAGTTGCTTTTTAAAAACGC
		TGCAGCATTACTATTACAATCTGCTAACATAGCATATTGAAATGCTATATC
		ACTGTCATCTGTTAACTCATTATCAAATGCCCATTGTACCATGTCTGATAA
		ATCAAATACACTATCATCTATTCCATGTTGTATTATGGTTAATCTTTTTATC
		CATTCCGGCGTGTCGCCACACACCTCACTAATATTAGATATTCCTGTTCTA
		TACCAATATAATGCTGCAACAGGGCTACGTAATTTTGGTGGCTGCAAAAG
		CATACAGCTGTCTGGAACATGCAACAATGTACTCAATCCTTTTCCTACTGT
		TATTCTATTTTTTCCACATTTGTATCTTATTAGCATTAGTATTAATATTCCA
		GTTTTTGTATCTAAACATTGTATATGGGTATACAATGCATATTGTTTAATTA
		GTGTTTTAAACCCTTCCGCAATGGTTGGATTTACTCCAAATATTGCTGCTA
		CCCAGTCTGTACATGTGGTTTTATCACTTTTAAAT

56	HPV68	GCAAATAACTGTTCCCTACGTAAACAAAAAAACATACTGTCTCCATAC
	[450 bp]	ACATCTGCAGACATTTGCAAATAGTCAGGATATTTGCAAACAGATTGACA
		TATATCCAAAGGTACCTCGCTTTTCGTTTCTTGTAATGTACCAAAGTCCAT
		AGCACCATATCCTGTATCAATCATATCGCCATCCTCAATAGGAGTATTTAC
		CAATTCCAATGGGGGACAGTCCCCTTGTTGTACATTGGTAGGCTTACAAGA
		TTTACCTTTGGCCCAGTGCTCGCCAATAGCAGGAACACAGCCTATAATACA
		CAGCTGTGTTTGTTTACAGTCCACTGCAACATTGTCCCTACTGTCTTTAGG
		ATTTTTATTAGAGGAAAACGGGGAATTTTCAGTATCATCCAGCCTATTATA
		TAGTGGATGCCCACTAAGGCCAACGCCCAATGGCTGCCCCCTACCT
		ATGTTGGCTTTGGAGCCATGGATTTTAAAGCTTTACAAGCAAATAAAA
		GTGATGTACCTATTGATATTTCTAACACTACCTGTAAATACCCAGATTATT
		TAGGCATGGCTGCTGATCCCTATGGTGATTCCATGTGGTTTTATCTTCGTA

57	HPV73	GGGAACAAATGTTTGTTCGACACTTATTTAACAGGGCTGGTGATACCGGT
	[640 bp]	GATAAAATCCCAGATGACCTAATGATTAAAGGCACAGGCAATACTGCAAC
		ACCATCCAGTTGTGTTTTTTATCCTACACCTAGTGGTTCCATGGTTTCTTCA
		GATGCACAGTTGTTTAATAAACCTTATTGGTTGCAAAAGGCACAGGGACA
		AAATAATGGTATTTGTTGGCATAATCAATTATTTTTAACTGTTGTAGATAC
		TACTAGAAGCACTAATTTTTCTGTATGTGTAGGTACACAGGCTAGTAGCTC
		TACTACAACGTATGCCAACTCTAATTTTAAGGAATATTTAAGACATGCAGA
		AGAGTTTGATTTACAGTTTGTTTTTCAGTTATGTAAAATTAGTTTAACTACT
		GAGGTAATGACATATATACATTCTATGAATTCTACTATATTGGAAGAGTGG
		AATTTTGGTCTTACCCCACCACCGTCAGGTAC

Linear probes are then generated from the plasmids. This can be accomplished in a number of ways, including but not limited to: cleaving the plasmid with, for example, a restriction endonuclease and/or amplifying a portion of the plasmid by, for example, sequence-specific polymerase chain reaction.
In one embodiment, the probes are generated by (1) linearizing the plasmid through the use of a restriction endonuclease, then (2) amplifying the probe portion of the plasmid using a polymerase and a polymerase specific promoter. For example, linearized RNA probes can be generated from the plasmids in FIGS. 22-29 by first cleaving the plasmid with XhoI restriction endonuclease, then transcribing the portion specific for HPV nucleic acids with T7 RNA polymerase. This is depicted at FIG. 31.
3. Test for Cross-Reactivity with LR-HPV
An in vitro transcription RNA probe set was generated from the truncated plasmids were tested according to the method described in Example 1 to the probe set to determine if cross-reactivity with LR-HPV was reduced or eliminated. A second deletion was made if significant cross-reactivity was still apparent after the first deletion. The deletion primer sequences are set forth in the following table:

TABLE 3

	SEQ ID
HPV	NO	SEQUENCE

26X

	58	5′ GTATTTCAATTGCCTGCCATGCCGTGTAACACTGTTTACATGTGTGTC 3′
	118	3′ GCTGACGTTACGATATACATAAAGTTAACGGACGGTACGGCA 5′

26XX	60	5′ GTTTCGGCCGTGTAACCAGTATGGCTTATTAAATAGTTGT 3′
	119	3′ ATTCCCTGCAAACCACGGATCAAAGCCGGCACATTGGTCA 5′

33X	62	5′ TTTATCTAATGTCTTACTAATTCCATAAAACTTATTCCAT 3′
	63	3′ ACCGAACATGATATGACACTAAATGAATTACAGAATGATT 5′

52X	64	5′ GAAACACATATGGAAGGAAATTTATTTACTTGGTGAGTGT 3′
	65	3′ GTGTCGACAATTTATATGGTCTTTGTGTATACCTTCCTTT 5′

58X	66	5′ TAGACCATTTATTGAACATTGGAAACTAATACGCATGGAG 3′
	67	3′ CATTCAAAATACCTTAATCAATCTGGTAAATAACTTGTAA 5

39X	68	5′ AATGCTAATAACTTACTACCGAATTATCAAACACCACCGC 3′
	69	3′ TTTGTTCCTCATGATTAAAATTACGATTATTGAATGATGG 5′

39XX	70	5′ GTCACCCACCTATCAATCATATCACCATCCTCAATAGGGG 3′
	71	3′ ATGTTAACCCGTCCTTACCGCAGTGGGTGGATAGTTAGTA 5′

56X	72	5′ CAATTTACAACCGTGGGCAACCAAGACGCCGCAGTATCC 3′
	73	3′ GTCCTGAACAAATTTTCATCGTTAAATGTTGGCACCCGT 5′

56XX	74	5′ ATGAATTACAATATAAATTTTGGGATGTTAACTTACAGGA 3′
	75	3′ GGAATCTGTACACCTCCTTATACTTAATGTTATATTTAAA 5′

66X	76	5′ AGGAACTATTGAAGGACAACATATAGAAGTGTGGTTTGAT 3′
	77	3′ TTGTGGTTGTGTGGTTAACGTCCTTGATAACTTCCTGTTG 5′

66XX	78	5′ CTGAGGTGCCAGGTATTTGTTACTGTTGTGGATACTACCA 3′
	79	3′ CGTTAATGTCCTTAGTTTCCGACTCCACGGTCCATAAACA 5′

68X	80	5′ CTGGTACGTACGACGTCGTCTCGGAAGTATCCCAGACAGT 3′
	81	3′ TACCTAACAGTAAATTACTGGACCATGCATGCTGCAGCAG 5′

68XX	82	5′ AAAATGCCTGATTTCAACACCAACACAGGCCCATACCATG 3′
	83	3′ TGGTACGGAGGGGATAAGGTTTTTACGGACTAAAGTTGTG 5′

73X	84	5′ ATTGCTAGCACAGTAGAGGTTAGATATGACTGTGAAAAGG 3′
	85	3′ TCCTTATTACGTTTTCGTCGTAACGATCGTGTCATCTCCA 5′

73XX	86	5′ TTCCTCTAAACTATCATATCACCATCCTGTATAGGGGTGT 3′
	87	3′ CTACAATGTATAGATATACAAAGGAGATTTGATAGTATAG 5′

Among the selected plasmids, the total amount of deleted sequence contained in the one (X) or two (XX) deletions ranged from ˜1.4 to 2.4 Kb. The final plasmid constructs resulted in HPV 33X, 52X, 58X with single deletions and HPV 26XX, 39XX, 56XX, 66XX, 68XX and 73XX with double deletions. Restriction maps of the plasmids and resultant probes are set forth in FIGS. 10 through 18. Exemplary deletions are shown above at Table 2.

4. Exemplary Workflow for Double Deletion of HPV26

An example of this workflow for generating an HPV26 double strategically-truncated plasmid is depicted at FIGS. 19 and 20. A pBluescript II KS(+) plasmid bearing an HPV26 sequence according to GenBank accession number X74472 was used as starting material. After methylation, the plasmid is amplified with the following pair of deletion primers:

Forward Primer (SEQ ID NO: 58):

5′ GTATTTCAATTGCCTGCCATGCCGTGTAACACTGTTTACATGTGTG

TC

3′

Reverse Primer (SEQ ID NO: 118):

5′ ACGGCATGGCAGGCAATTGAAATACATATAGCATTG CAGTCG 3′

The result of this amplification deletes a 1510 base pair section of the plasmid, resulting in truncations of the E1 and E2 regions. This amplicon is then transfected into a strain of DH5α™-T1^R E. coli bearing an active form of McrBC nuclease (Invitrogen Corp., Carlsbad, Calif.) to generate an HPV26X strategically-truncated plasmid.
A second amplification is then performed with the following pair of deletion primers:

	Forward Primer (SEQ ID NO: 60):
	5′ GTTTCGGCCGTGTAACCAGTATGGCTTATTAAATAGTTGT 3′

	Reverse Primer (SEQ ID NO: 119):
	5′ ACTGGTTACACGGCCGAAACTAGGCACCAAACGTCCCTTA 3′

This amplification deletes a 490 base pair section of the plasmid, resulting in truncation of the L1 region.

This amplicon was then transfected into a strain of DH5α™-T1^R E. coli bearing an active form of McrBC nuclease (Invitrogen Corp., Carlsbad, Calif.). The E. coli circularizes the amplicons to generate an HPV26XX strategically-truncated plasmid, while McrBC digests the methylated template.
The HPV26XX plasmid was restriction mapped to confirm the structure and size. The plasmid was digested with (1) XhoI only; (2) XhoI and NotI; (3) BamHI and SpeI; and (4) HindIII. The results are shown at FIG. 21. This plasmid has the features set forth below in Table 3:

TABLE 4

	Starts At	Ends At
Name	(nucleotide)	(nucleotide)	Coding Strand

Coding sequences	Ampicillin	1233	2093	Complementary
(7 total)	Resistance Gene
	L2	2878	4296	Complementary
	Truncated E2	4622	5521	Complementary
	E1/E2 Deletion	5542	5542	Not Applicable
	(1510 bp deletion)
	Truncated E1	5538	6093	Complementary
	E7	6101	6415	Complementary
	E6	6422	6860	Complementary
	L1 Deletion	7809	7809	Not Applicable
	(490 bp deletion)
	Truncated L1	7796	8818	Complementary
Misc. Feature	pBluescript II		1	2891	Not Applicable
(1 total)	KS(+)
Prokaryotic Promoter	T7 Promoter	2855	2874	Not Applicable
(1 total)

Example 2

Assay Using Cervical Samples and HPV Probes

A total of 324 physician collected cervical samples were collected in a detergent based collection medium and tested for the presence of high-risk HPV.
A 1 ml sample was vortexed to homogenize the sample and a 50 μl aliquot was removed and combined with 25 μl of denaturation reagent (1.75 N NaOH) in the assay microplate. This was shaken to mix and incubated at 70° C. for 30 minutes to create single stranded DNA. To this, 40 μl of a neutralization buffer (probe diluent −2.2M BES, 2.6% PAA, 0.7 N NaOH and 0.09% sodium azide) containing RNA probes for 16 HPV types was added to create a neutral pH and incubated at 68.5° C. for 10 minutes.
Following this, 10 μl of antibody conjugated paramagnetic beads (approximately 1 μm carboxylated SERADYN beads from Thermo Fisher) were added to the reaction and incubated for an additional 30 minutes at 68.5° C. The RNA probes and DNA target molecules that were complementary to each other bind and create RNA-DNA hybrids. The hybrids then captured by a RNA-DNA hybrid specific antibody coated on the paramagnetic SERADYN beads.
Following incubation, the paramagnetic beads are separated from the liquid phase/supernatant by exposure to a magnetic field. The supernatant waste is removed by decanting and 35 μl of detection reagent 1 (secondary antibody conjugated enzyme comprising a monoclonal anti-RNA-DNA hybrid antibody conjugated to alkaline phosphatase) is added and incubated at 45° C. for 30 minutes. The secondary antibody binds the RNA-DNA hybrid-antibody-conjugated paramagnetic bead complex. Non-bound secondary antibody is washed away using a detergent based wash buffer (40 mM Tris, pH 8.2, 100 mM NaCl, 0.1% Triton-X 100 and 0.09% sodium azide).
A substrate (dioxetane-based substrate from ABI, called DCP Star, with Emerald II enhancer) is added to the washed beads and wells that contain high-risk HPV DNA create light that is detectable by a luminometer and measured in RLUs (relative light units). An assay positive standard containing 1 pg/ml of HPV DNA is used to establish the positive cutoff. All sample RLU values are divided by the RLU value for the positive standard creating a RLU/CO (RLU to cutoff value). Results are reported in RLU/CO and anything greater than or equal to 1.0 is considered positive.

Example 3

Stability Testing

Following initial testing, samples were stored at room temperature and 33° C. to observe the stability of the samples. Testing was conducted as far as 21 days post collection. FIGS. 3 and 4 demonstrate that the RLU/CO value for each sample does not change with time up to 21 days. A 2×2 analysis comparing baseline results to the results after 21 days of storage and scatter plot analysis demonstrated the linearity of the RLU/CO values with time. Based on these data, it is possible to conclude that samples collected and stored at either room temperature or 33° C. for as long as 21 days provide comparable RLU/CO values as tested at baseline. Using linear mixed model comparison of RLU/CO values against the temperature of storage the P values are 0.8803 for room temperature and 0.9517 for samples stored at 33° C. indicating that values are equal.

Example 4

This example describes the limit of detection (LOD), the C₉₅concentration, and cross-reactivity experiments using re-engineered HYBRID CAPTURE chemistry and high risk (HR) and low-risk (LR) HPV plasmid DNA constructs. LOD is defined as the copy number required to identify whether virus is detected. The C₉₅concentration is defined as the copy number required to identify whether the signal for the specimen is above a presumptive clinical cutoff 95% of the time.
Two independent assays using full length complementary RNA probes that hybridize to either HPV 16 or HPV 18 and HPV45 DNA were conducted. LOD and the C₉₅concentration were determined using serial dilutions of HPV 16, HPV18, and HPV45 genomic DNA and testing with the complementary RNA probes. Cross reactivity was determined using genomic DNA from LR and HR HPV types diluted to approximately 1×10⁷copies per reaction and testing with HPV16, HPV18, and HPV45 RNA probes.

TABLE 5

Limit of Detection and C₉₅ Concentration

Probe

HPV

16	HPV 18/45	HPV 18/45
	Target	16	18	45

Copy	LOD	564	604	533
No.	C₉₅	8,464	8,464	7,444

TABLE 6

High Risk Type Cross Reactivity

Signal to Cutoff Ratios

	HR Target Type	HPV	16	HPV 18/45

→ HPV 16	172.47*	0.13
→ HPV 18	0.22	93.87*
HPV 26	0.14	0.16
HPV 31	0.19	0.19
HPV 33	0.15	0.21
HPV 35	0.23	0.20
HPV 39	0.15	0.19
→ HPV 45	0.19	146.92*
HPV 51	0.15	0.24
HPV 52	0.15	0.20
HPV 56	0.15	0.20
HPV 58	0.15	0.19
HPV 59	0.15	0.20
HPV 66	0.15	0.20
HPV68	0.15	0.27
HPV73	0.20	0.15
HPV82	0.14	0.15

*where RLU/CO > 1 = Positive

TABLE 7

Low Risk Type Cross Reactivity

Signal to Cutoff Ratios

HR Target Type	HPV	16	HPV 18/45

HPV 1	0.32	0.34
HPV 2	0.34	0.37
HPV 3	0.39	0.39
HPV 4	0.27	0.26
HPV 5-9	0.28	0.34
HPV 5-48	0.20	0.23
HPV 8	0.27	0.33
HPV 30	0.26	0.27
HPV 34	0.17	0.20
HPV 40	0.35	0.34
HPV 42	0.15	0.15
HPV 44	0.21	0.33
HPV 53	0.28	0.35
HPV 61	0.42	0.48
HPV 62-116	0.58	0.15
HPV 62-177	0.24	0.14
HPV 67	0.23	0.29
HPV 69	0.46	0.41
HPV 70	0.14	0.15
HPV 81	0.55	0.51

Cervical specimens were collected at an external clinic site and placed into digene collection medium (DCM) per routine clinical procedure. Specimens were tested using the hybrid capture HR HPV DNA screening assay, and the reactive specimens and a subset of the non-reactive specimens were assayed using the hybrid capture HPV16 and HPV18/45 genotyping assays. A subset of the reactive specimens were also evaluated using HPV genotyping by GP5+/6+ PCR followed by Luminex detection. Any of the detergent-based collection medium described herein may be used, for example, the media may contain 1.0% NP-40, 0.25% sodium deoxycholate, 50 mM Tris-HCl, 25 mM EDTA, 150 mM NaCl and 0.05% sodium azide.

TABLE 8

Representative Clinical Specimen Data

	HR Screen	HPV	16	HPV 18/45
ID	RLU/CO	RLU/CO	RLU/CO	High Risk Genotype	Low Risk Genotype

3350	366.8*	156.7*	0.28	16			Neg
3696	283.9*	0.50	0.20	35			Neg
3631	278.0*	328.2*	0.20	16			40
3419	211.2*	0.12	0.15	52			Neg
3711	205.2*	0.13	0.22	56			Neg
3355	158.2*	0.16	0.15	51			74	83	91
3718	154.8*	0.19	117.0*	18			Neg
3463	141.8*	0.13	0.15	66			Neg
3514	124.8*	106.8*	0.17	16			Neg
3637	65.8*	0.17	0.16	68			Neg
3576	50.6*	0.13	0.13	52			32	42	62	67	90
3656	47.3*	0.14	0.22	31			54	72
3415	10.2*	0.13	0.15	82			28	85	86
3366	9.6*	0.11	5.4*	18	35	45	42	86	87
3434	8.6*	0.14	5.2*	33	45		72	87
3229	8.4*	15.7*	0.14	16			Neg
3705	0.25	0.27	0.10	Neg			Neg
3239	0.25	0.13	0.12	Neg			69
3717	0.23	0.17	0.17	Neg			Neg
3719	0.22	0.10	0.13	Neg			32

Example 5

This example demonstrates the reduction of cross-reactivity of the 17 full length (B17FL) Probe cocktail compared with the strategically-truncated probe cocktail (B17XX) against eight low risk HPV types. Low risk HPV plasmid types 30, 40, 53, 61, 67, 69, 71, and 81 were used as targets at concentrations were tested: 0.5, 1, and 2 ng/mL. Results are summarized in Table 9 below.

	TABLE 9

	B17 FL	B17 XX

0.5	1	2	0.5	1	2
ng/mL	ng/mL	ng/mL	ng/mL	ng/mL	ng/mL

HPV

30	0.62	0.43	1.05	0.29	0.37	0.58
HPV 40	0.31	0.29	0.45	0.24	0.31	0.45
HPV 53	0.84	1.39	2.44	0.77	1.23	1.99
HPV 61	0.40	0.49	0.81	0.33	0.39	0.72
HPV 67	0.43	0.73	1.25	0.27	0.43	0.62
HPV 69	4.01	7.90	14.97	0.73	1.08	3.09
HPV 71	0.24	0.27	0.28	0.20	0.20	0.22
HPV 81	0.37	0.48	0.90	0.21	0.26	0.49

Readout is shown in RLU/CO. All reactions having an RLU/CO greater than or equal to 1 are considered to have a high degree of cross-reactivity. As can be seen, in all cases, the full-length probe cocktail exhibited higher cross-reactivity than the corresponding strategically-truncated probe cocktail. In addition, the following full-length probes displayed a high degree of cross-reactivity: HPV 30 at 2 ng/mL; HPV 53 at 1 ng/mL, and HPV 67 at <0.5 ng/mL. This high cross-reactivity was either reduced or eliminated with the strategically-truncated probes.

Claims

1. A polynucleotide probe comprising at least one sequence having from 70% to 100% complementarity to at least 100 contiguous bases of each of L1, L2, E1, E2, E4, E6, and E7 of a high risk HPV nucleic acid, wherein said polynucleotide probe does not cross-react with a low risk HPV nucleic acid.

2. The polynucleotide probe of claim 1, with the proviso that said polynucleotide probe does not contain any sequences of at least 100 contiguous bases having about 70% to 100% complementarity to at least 100 contiguous bases of a low risk HPV nucleic acid.

3. The polynucleotide probe according to claim 1 wherein the low risk HPV nucleic acid is selected from the group consisting of SEQ ID NO: 18 to SEQ ID NO: 43 and complements thereof.

4. The polynucleotide probe according to claim 1, wherein said high risk HPV nucleic acid is selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 17, SEQ ID NO: 104 to SEQ ID NO: 110, SEQ ID NO: 116, and complements thereof.

5. The polynucleotide probe of claim 1, wherein said polynucleotide probe does not comprise any sequences having about 70% to 100% identity to SEQ ID NO: 44 to SEQ ID NO: 57, SEQ ID NO: 111 to SEQ ID NO: 115, and complements thereof.

6. The polynucleotide probe of claim 1 comprising a sequence having about 70% to 100% identity to a sequence selected from the group consisting of SEQ ID NO: 97 to SEQ ID NO: 103, SEQ ID NO: 117, and complements thereof.

7. The polynucleotide probe of claim 1 consisting essentially of a sequence selected from the group consisting of SEQ ID NO: 97 to SEQ ID NO: 103, SEQ ID NO: 117, and complements thereof.

8. The polynucleotide probe of claim 1 consisting of a sequence selected from the group consisting of SEQ ID NO: 97 to SEQ ID NO: 103, SEQ ID NO: 117, and complements thereof.

9. A kit comprising at least one polynucleotide probe of claim 1.

10. A method for generating a polynucleotide probe specific for a high risk HPV nucleic acid, said method comprising:

a) providing a template nucleic acid comprising a sequence at least 1 kilobase in length sharing from about 70% to 100% identity with at least a portion of the high risk HPV nucleic acid;

b) comparing the sequence of the template nucleic acid with at least one low risk nucleic acid; and

c) truncating the template nucleic acid to remove any regions of the template nucleic acid that share from about 70% to 100% identity over 100 contiguous base pairs with a region of the low risk HPV nucleic acid.

11. The method of claim 10 wherein the template nucleic acid is truncated by amplifying the template nucleic acid using a deletion primer.

12. The method of claim 11 wherein the template nucleic acid is methylated before the template nucleic acid is amplified.

13. The method of claim 12 wherein the methylated template nucleic acid is selectively digested.

14. A polynucleotide probe generated according to the method of claim 9.

15. A nucleic acid probe set generated by fragmenting a polynucleotide probe of claim 1.

16. A kit comprising a nucleic probe set of claim 15.

17. A method for determining the presence of a target nucleic acid in a sample, the method comprising:

a) hybridizing at least one polynucleotide probe according to claim 1 to the target nucleic acid molecule to form a double-stranded nucleic acid hybrid;

b) capturing the double-stranded nucleic acid hybrid on a support, wherein the support comprises a first antibody specific for a double-stranded nucleic acid hybrid; and

c) detecting the target nucleic acid molecule.

18. The method of claim 17, wherein the double stranded nucleic acid hybrid is a DNA:RNA hybrid.

19. The method of claim 17 wherein the target nucleic acid is a high risk HPV nucleic acid.

20. The method of any of claim 17 wherein the sample is a biological sample.